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A B S T R A C T
Background
The benefits of erythropoiesis-stimulating agents (ESA) for chronic kidney disease (CKD) patients have been previously demonstrated.
However, the eCicacy and safety of short-acting epoetins administered at larger doses and reduced frequency as well as of new epoetins
and biosimilars remains uncertain.
Objectives
This review aimed to evaluate the benefits and harms of diCerent routes, frequencies and doses of epoetins (epoetin alpha, epoetin beta
and other short-acting epoetins) for anaemia in adults and children with CKD not receiving dialysis.
Search methods
We searched the Cochrane Kidney and Transplant Specialised Register to 12 September 2016 through contact with the Information
Specialist using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies
specifically designed for CENTRAL, MEDLINE, and EMBASE; handsearching conference proceedings; and searching the International
Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.
Selection criteria
We included randomised control trials (RCTs) comparing diCerent frequencies, routes, doses and types of short-acting ESAs in CKD patients.
Data collection and analysis
Two authors independently assessed study eligibility and four authors assessed risk of bias and extracted data. Results were expressed as
risk ratio (RR) or risk diCerences (RD) with 95% confidence intervals (CI) for dichotomous outcomes. For continuous outcomes the mean
diCerence (MD) with 95% confidence intervals (CI) was used. Statistical analyses were performed using the random-eCects model.
Main results
We identified 14 RCTs (2616 participants); nine studies were multi-centre and two studies involved children. The risk of bias was high in
most studies; only three studies demonstrated adequate random sequence generation and only two studies were at low risk of bias for
allocation concealment. Blinding of participants and personnel was at low risk of bias in one study. Blinding of outcome assessment was
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judged at low risk in 13 studies as the outcome measures were reported as laboratory results and therefore unlikely to be influenced by
blinding. Attrition bias was at low risk of bias in eight studies while selective reporting was at low risk in six included studies.
Four interventions were compared: epoetin alpha or beta at diCerent frequencies using the same total dose (six studies); epoetin alpha at
the same frequency and diCerent total doses (two studies); epoetin alpha administered intravenously versus subcutaneous administration
(one study); epoetin alpha or beta versus other epoetins or biosimilars (five studies). One study compared both diCerent frequencies of
epoetin alpha at the same total dose and at the same frequency using diCerent total doses.
Data from only 7/14 studies could be included in our meta-analyses. There were no significant diCerences in final haemoglobin (Hb) levels
when dosing every two weeks was compared with weekly dosing (4 studies, 785 participants: MD -0.20 g/dL, 95% CI -0.33 to -0.07), when
four weekly dosing was compared with two weekly dosing (three studies, 671 participants: MD -0.16 g/dL, 95% CI -0.43 to 0.10) or when
diCerent total doses were administered at the same frequency (four weekly administration: one study, 144 participants: MD 0.17 g/dL 95%
CI -0.19 to 0.53).
Five studies evaluated diCerent interventions. One study compared epoetin theta with epoetin alpha and found no significant diCerences
in Hb levels (288 participants: MD -0.02 g/dL, 95% CI -0.25 to 0.21). One study found significantly higher pain scores with subcutaneous
epoetin alpha compared with epoetin beta. Two studies (165 participants) compared epoetin delta with epoetin alpha, with no results
available since the pharmaceutical company withdrew epoetin delta for commercial reasons. The fiMh study comparing the biosimilar
HX575 with epoetin alpha was stopped aMer patients receiving HX575 subcutaneously developed anti-epoetin antibodies and no results
were available.
Adverse events were poorly reported in all studies and did not diCer significantly within comparisons. Mortality was only detailed
adequately in four studies and only one study included quality of life data.
Authors' conclusions
Epoetin alpha given at higher doses for extended intervals (two or four weekly) is non-inferior to more frequent dosing intervals in
maintaining final Hb levels with no significant diCerences in adverse eCects in non-dialysed CKD patients. However the data are of low
methodological quality so that diCerences in eCicacy and safety cannot be excluded. Further large, well designed, RCTs with patient-
centred outcomes are required to assess the safety and eCicacy of large doses of the shorter acting ESAs, including biosimilars of epoetin
alpha, administered less frequently compared with more frequent administration of smaller doses in children and adults with CKD not
on dialysis.
P L A I N   L A N G U A G E   S U M M A R Y
Short-acting erythropoiesis agents in chronic kidney disease patients not requiring dialysis
What is the issue?
Anaemia due to reduced production by the kidneys of erythropoietin (a hormone which increases red cell production) is a major cause of
tiredness and other problems experienced by people with chronic kidney disease requiring or not requiring dialysis.
Manufactured erythropoietins (epoetins) improve anaemia and are oMen prescribed for people with chronic kidney disease. Several
diCerent manufactured epoetins are now available.
What did we do?
We searched the Cochrane Kidney and Transplant Specialised Register to 12 September 2016 through contact with the Information
Specialist using search terms relevant to this review. We included randomised control trials (RCTs) comparing diCerent frequencies, routes,
doses and types of short-acting ESAs in patients with chronic kidney disease.
What did we find?
We examined the evidence from 14 studies with 2616 participants with CKD not receiving dialysis published before 12 September 2016 to
determine whether diCerences in improvement in anaemia and in side eCects existed between diCerent short-acting epoetins or between
the same epoetins given at diCerent frequencies. We did not find any studies using diCerent frequencies of epoetins in children.
We found that the traditionally shorter acting epoetins given less oMen (two weekly to every four weeks) resulted in similar correction of
anaemia compared with administration every week or every two weeks; there were no diCerences in side eCects between the diCerent
comparisons. One study comparing subcutaneous administration of a newly manufactured HX575 epoetin alpha compared with epoetin
alpha was discontinued aMer two patients developed anti-erythropoietin antibodies. However more studies are required as most studies
were small and poorly designed, which limits their application to the care of patients.
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Summary of findings for the main comparison.   Epoetin alpha every 2 weeks versus to weekly for anaemia in CKD patients not receiving dialysis
Epoetin alpha every 2 weeks versus to weekly for anaemia in CKD patients not receiving dialysis
Patient or population: anaemia in predialysis patients
Intervention: epoetin alpha every 2 weeks
Comparison: weekly
Anticipated absolute effects* (95% CI)Outcomes
Risk with weekly Risk with Epoetin alpha every 2
weeks
Relative ef-
fect
(95% CI)
No. of partic-
ipants
(studies)
Quality of the
evidence
(GRADE)
Comments
Change in Hb
level
The mean change in Hb
level was 0 g/dL
The mean change in Hb level in the
intervention group was 0.19 g/dL
lower (0.32 g/dL lower to 0.06 g/dL
lower)
- 798 (4) ⊕⊕⊝⊝
LOW 1 2
downgraded for study limita-
tions and indirectness
Study population
960 per 1000 922 per 1000
(893 to 951)
Moderate
Number reach-
ing target Hb
947 per 1000 910 per 1000
(881 to 938)
RR 0.96
(0.93 to 0.99)
798 (4) ⊕⊕⊝⊝
LOW 1 2
downgraded for study limita-
tions and indirectness
Study population
28 per 1000 24 per 1000
(10 to 57)
Moderate
Number of
deaths
22 per 1000 20 per 1000
(9 to 46)
RR 0.89
(0.38 to 2.07)
838 (4) ⊕⊕⊝⊝
LOW 1 3
downgraded for study limita-
tions and imprecision
Study populationAdverse events:
RBC transfu-
sions 33 per 1000 52 per 1000
RR 1.56
(0.71 to 3.45)
580 (3) ⊕⊕⊝⊝
LOW 3 4
downgraded for imprecision
and study limitations
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(23 to 114)
Moderate
37 per 1000 58 per 1000
(26 to 128)
Study population
100 per 1000 85 per 1000
(55 to 132)
Moderate
Adverse events:
hypertension
95 per 1000 81 per 1000
(52 to 126)
RR 0.85
(0.55 to 1.32)
838 (4) ⊕⊕⊕⊝
MODERATE 1
downgraded for study limita-
tions
Study population
28 per 1000 39 per 1000
(18 to 83)
Moderate
Adverse events:
thrombovascu-
lar events
27 per 1000 38 per 1000
(18 to 80)
RR 1.41
(0.67 to 3.00)
838 (4) ⊕⊕⊝⊝
LOW 1 3
downgraded for study limita-
tions and imprecision
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio; Hb: haemoglobin; RBC: red blood cells
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 allocation concealment unclear in 3 of 4 studies
2 surrogate outcome
3 few studies with low numbers and wide confidence
4 allocation concealment unclear in 2 of 3 studies
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Summary of findings 2.   Epoetin alfa every four weeks versus with every two weeks in CKD patients not receiving dialysis
Epoetin alfa every four weeks versus with every two weeks in CKD patients not receiving dialysis
Patient or population: anaemia in predialysis patients
Intervention: epoetin alpha every 4 weeks
Comparison: every 2 weeks
Anticipated absolute effects* (95% CI)Outcomes
Risk with every 2 weeks Risk with Epoetin alpha every 4
weeks
Relative ef-
fect
(95% CI)
No. of partic-
ipants
(studies)
Quality of the
evidence
(GRADE)
Comments
Change in Hb
level
The mean change in Hb
level was 0
The mean change in Hb level in the
intervention group was 0.15g/dL
lower (0.41 g/dL lower to 0.1g/dL
more)
- 671 (3) ⊕⊝⊝⊝
VERY LOW 1 2 3
downgraded for study limita-
tions, heterogeneity and indi-
rectness
Study population
916 per 1000 870 per 1000
(769 to 980)
Moderate
Number reach-
ing target Hb
895 per 1000 850 per 1000
(752 to 957)
RR 0.95
(0.84 to 1.07)
687 (3) ⊕⊝⊝⊝
VERY LOW 1 2 3
downgraded for study limita-
tions, heterogeneity and indi-
rectness
Study population
22 per 1000 21 per 1000
(7 to 62)
Moderate
Number of
deaths
26 per 1000 25 per 1000
(9 to 72)
RR 0.95
(0.33 to 2.75)
724 (3) ⊕⊕⊝⊝
LOW 1 4
downgraded for study limita-
tions, imprecision
Study populationAdverse events:
RBC transfu-
sions 38 per 1000 48 per 1000
(20 to 114)
RR 1.26
(0.53 to 2.98)
470 (2) ⊕⊕⊝⊝
LOW 1 4
downgraded for study limita-
tions, imprecision
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Moderate
35 per 1000 44 per 1000
(18 to 103)
Study population
70 per 1000 72 per 1000
(44 to 119)
Moderate
Adverse events:
hypertension
62 per 1000 63 per 1000
(38 to 104)
RR 1.02
(0.62 to 1.69)
724 (3) ⊕⊕⊕⊝
MODERATE 1
downgraded for study limita-
tions
Study population
26 per 1000 26 per 1000
(10 to 68)
Moderate
Adverse events:
arteriovenous
complications
23 per 1000 24 per 1000
(9 to 62)
RR 1.02
(0.39 to 2.68)
724 (3) ⊕⊕⊝⊝
LOW 1 4
downgraded for study limita-
tions, imprecision
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio; Hb: haemoglobin; RBC: red blood cells
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 two of the three studies had unclear allocation concealment
2 surrogate outcome
3 unexplained heterogeneity
4 small numbers with wide confidence intervals
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Summary of findings 3.   Epoetin theta versus epoetin beta in CKD patients not receiving dialysis
Epoetin theta versus epoetin beta in CKD patients not receiving dialysis
Patient or population: anaemia in predialysis patients
Intervention: epoetin theta
Comparison: epoetin beta
Anticipated absolute effects* (95% CI)Outcomes
Risk with epoetin beta Risk with Epoetin theta
Relative ef-
fect
(95% CI)
No. of partic-
ipants
(studies)
Quality of the
evidence
(GRADE)
Comments
Final Hb The mean final Hb was 0
g/dL
The mean final Hb in the intervention
group was 0.02 g/dL lower (0.25 g/dL low-
er to 0.21 g/dL higher)
- 288 (1) ⊕⊕⊕⊝
MODERATE 1
downgraded for indi-
rectness - surrogate out-
comes
Mean weekly
epoetin dose
The mean weekly epoetin
dose was 0 units/week
The mean weekly epoetin dose in the in-
tervention group was 0.4 units per week
higher (5.68 units per week lower 6.48
units/week higher)
- 288 (1) ⊕⊕⊝⊝
LOW 1 2
downgraded for indi-
rectness - surrogate out-
comes and imprecision
Study population
11 per 1000 26 per 1000
(3 to 219)
Moderate
Deaths
11 per 1000 26 per 1000
(3 to 218)
RR 2.46
(0.29 to 20.77)
288 (1) ⊕⊕⊝⊝
LOW 2
downgraded for impreci-
sion
Study population
74 per 1000 26 per 1000
(8 to 80)
Moderate
Adverse events:
hypertension
74 per 1000 26 per 1000
(8 to 80)
RR 0.35
(0.11 to 1.08)
288 (1) ⊕⊕⊕⊝
MODERATE 2
downgraded for impreci-
sion
Study populationAdverse events:
RBC transfu-
sions 0 per 1000 0 per 1000
RR 1.48
(0.06 to 36.10)
288 (1) ⊕⊕⊝⊝
LOW 2
downgraded for impreci-
sion
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(0 to 0)
Study population
53 per 1000 93 per 1000
(36 to 244)
Moderate
Adverse events:
discontinuation
of therapy
53 per 1000 93 per 1000
(36 to 244)
RR 1.77
(0.68 to 4.63)
288 (1) ⊕⊕⊝⊝
LOW 2
downgraded for impreci-
sion
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio; RBC: red blood cells
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Surrogate outcome, not a patient-centred outcome
2 Small numbers, wide confidence intervals
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B A C K G R O U N D
Description of the condition
Anaemia is defined as haemoglobin (Hb) levels < 12.0 g/dL and
13.0 g/dL in adult females and males respectively based on the
World Health Organization's definition of anaemia (KDIGO 2012;
WHO 2011). Anaemia is diagnosed in children with chronic kidney
disease (CKD) if Hb concentration is < 11.0 g/dL in children aged
from six months to five years, < 11.5 g/dL in children aged five
to 12 years, and < 12.0 g/dL in children from 12 to 15 years of
age according to the Kidney Disease Improving Global Outcomes
guidelines (KDIGO 2012). Anaemia is a known complication of
CKD (Dmtrieva 2013) which develops as kidney function declines;
prevalence increases as glomerular filtration rate (GFR) falls. CKD
stage 3 to 5 is a predictor variable of decline in Hb (Dmtrieva 2013).
Anaemia prevalence ranges from 25% to 70% (Hsu 2002; Koch
1991), and most people with CKD stage 5 (GFR < 15 mL/min/1.73
m2) are anaemic (Astor 2002). Anaemia related to CKD results
in significant morbidity, mortality and increased cardiovascular
events, with symptoms including lack of energy, breathlessness,
dizziness, angina, poor appetite and decreased exercise tolerance
(Canadian EPO 1990; Lundin 1989).
The primary cause of anaemia in CKD is decreased production
of the naturally-occurring hormone, erythropoietin (EPO) in the
kidney. Anaemia may be exacerbated by concurrent iron deficiency
anaemia (KDIGO 2012).
Prior to the availability of recombinant human EPO (rHuEPO),
anaemia was managed with blood transfusions together with iron
and folate supplements. Cloning of the human gene for EPO was
achieved in 1983 (Lin 1985) and production of rHuEPO followed.
The eCicacy of erythropoiesis-stimulating agents (ESA) treatment
in dialysis patients was demonstrated in 1986 (Winearls 1986) and
several randomised controlled trials (RCTs) have documented a
beneficial eCect of ESA treatment in correcting the anaemia of CKD
in non-dialysis patients (Cody 2005; Stone 1988).
The increase in Hb levels following treatment with ESA leads
to improved energy levels (Wolcott 1989), improved cardiac
performance and increased ejection fraction (Pappas 2008) with
normalisation of cardiac output and reduced leM ventricular mass
(Cannella 1990). The benefits of early treatment of anaemia with
ESA in predialysis patients include increased exercise capacity,
improved quality of life, improved cognitive function and a slower
decline in kidney function (Ritz 2000; Roth 1994).
Description of the intervention
Administration of an ESA aims to replace endogenous EPO
production, raise Hb levels and alleviate signs and symptoms of
anaemia. Epoetin alpha has proven eCicacy in treating anaemia in
people with CKD (Eschbach 1987). Epoetin alpha has a relatively
short half-life and typically is administered twice or thrice weekly
(Locatelli 2011). More recently new longer acting ESAs, which can
be administered less frequently than short-acting ESAs, have been
developed allowing administration of ESA every one to four weeks
depending on the preparation used and the individual patient
response. Darbepoetin was the first ESA with a prolonged half-
life to enter the market enabling administration once a week
to four weekly (Macdougall 1999). More recently, the use of the
continuous EPO receptor activator (CERA), a pegylated epoetin, has
extended dosing intervals to one dose every two to four weeks
(Macdougall 2005). ESAs have to be administered intravenously or
subcutaneously so the benefits of using ESAs in non-dialysis CKD
patients, who will generally receive subcutaneous injections in an
outpatient setting, must be balanced against the inconvenience
and/or discomfort of injections as well as potential harms of
ESAs, which include hypertension, vascular access thrombosis and
cardiovascular events. A significant concern in ESA therapy is the
Hb target to be achieved. The CHOIR study reported a target Hb
level of 13.5 g/dL compared with 11.3 g/dL was associated with
increased mortality and cardiovascular risk and no considerable
improvement in the quality of life. The study could not provide an
explanation for poorer outcomes in patients with a higher target
Hb (Singh 2006). Recommendations on when to commence ESA
therapy are outlined in the KDIGO guidelines (KDIGO 2012). As
the patents for epoetin alpha have expired, cheaper biosimilars
of epoetin alpha have been developed. These biological products
are highly similar though not identical to reference products
and undergo a more limited appraisal before receiving marketing
approval. As they are not generic versions of the reference products
and could have diCerences particularly in adverse eCects, these
products should be submitted to rigorous assessment before
marketing and to long term monitoring to ensure that adverse
eCects are recognised and attributed to the responsible biological
preparation (Mikhail 2013; Schellekens 2009).
How the intervention might work
The primary cause of anaemia in CKD is the relative insuCiciency
of EPO which is mainly produced by peritubular fibroblasts in the
kidney. EPO is part of a widespread system of hypoxia-inducible
gene expression mediated by hypoxia-inducible transcription
factors (HIFs).The factors associated with inadequate EPO
production in progressive CKD remain unclear, though recent
data indicate a deranged oxygen sensing, in addition to loss of
EPO production, is involved (Bernhardt 2010). ESAs accelerate
erythropoiesis, increase iron utilisation and raise Hb levels with
clinical improvement in signs and symptoms of anaemia and
avoidance of blood transfusions. ESA therapy aims to increase
Hb levels slowly at a rate of 1 to 2 g/dL per month to correct
anaemia. AMer correction of anaemia, dose adjustment may be
necessary to maintain a stable Hb level. Anaemia is corrected slowly
with ESA to avoid major side eCects including hypertension and
thrombotic events. ESA requirements are diCicult to predict in
individual patients, and may be increased in people with associated
co-morbidities including cardiovascular disease, diabetes, chronic
inflammation and severe secondary hyperparathyroidism. ESA
requirements are generally lower in patients not receiving dialysis.
A major issue in ESA use relates to the Hb target to be
achieved with increased cardiovascular risk noted with higher
Hb targets (Drueke 2006; Singh 2006). Recent systematic reviews
have suggested that aiming for Hb levels similar to those seen
in healthy adults is associated with a significantly higher risk
of mortality due to cardiovascular events, such as stroke and
hypertension (Palmer 2010). The mechanisms for these treatment-
related harms are poorly understood though observational studies
suggest treatment related toxicity secondary to impaired Hb
responses and incremental erythropoietin dosing (Szczech 2008).
KDIGO guidelines (KDIGO 2012) recommend that in general ESAs
should not be used to raise Hb levels > 11.5 g/dL.
Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients (Review)
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Why it is important to do this review
In a previous Cochrane systematic review, which included 15 RCTs,
rHuEPO (epoetin alpha) significantly increased Hb (two studies)
or haematocrit (HCT) levels (five studies) compared with placebo
or no treatment and significantly reduced blood transfusion
requirements (Cody 2005). Determining the ESA agent to be
used should include assessment of the drug's pharmacodynamics,
pharmacokinetics, route and frequency of administration, adverse
eCects, availability and any economic issues (KDIGO 2012). In most
high income countries, the use of short-acting ESAs (epoetin alpha,
epoetin beta) in patients with CKD has been superseded by longer
acting ESAs (darbepoetin, CERA) because of the reduced frequency
of administration. In low income countries where newer longer
acting ESAs are less likely to be accessible, clinicians may be limited
to use short-acting ESAs. The cost of using newer ESAs agents
would have to be balanced against the costs and inconvenience
of more frequent administration. Since the eCicacy and safety of
rHuEPO compared with placebo or no treatment has already been
demonstrated (Cody 2005), this review aims to evaluate short-
acting ESAs (epoetin alpha, epoetin beta, other epoetins or epoetin
biosimilars) in patients, both adults and children with CKD not on
dialysis (CKD stages 2 to 5) with reference to route of administration
(intravenous versus subcutaneous), frequency of administration,
diCerent doses and direct comparisons of diCerent epoetins to
provide additional information about the value of these agents for
institutions where shorter acting ESAs are used.
This review will not evaluate studies comparing short-acting with
longer acting ESAs in CKD, diCerent longer acting ESAs in CKD,
diCerent routes of administration in dialysis patients or kidney
transplant recipients and diCerent Hb targets as these are subject
of other Cochrane published or planned systematic reviews (Hahn
2014; Palmer 2012; Palmer 2014a; Palmer 2014b; Strippoli 2006).
O B J E C T I V E S
This review aimed to evaluate the benefits and harms of diCerent
routes, frequencies and doses of epoetins (epoetin alpha, epoetin
beta and other short-acting epoetins) for anaemia in adults and
children with CKD not receiving dialysis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All RCTs and quasi-RCTs (RCTs in which allocation to treatment
was obtained by alternation, use of alternate medical records, date
of birth or other predictable methods) looking at epoetins (short-
acting ESAs) for treatment of anaemia in patients with CKD not on
dialysis.
Types of participants
Inclusion criteria
Patients of any age (adults and children) with anaemia due to CKD
(stages 2 to 5) of any severity, who were not receiving dialysis, were
included. The definitions of CKD and anaemia used in individual
studies were used in this review.
Exclusion criteria
Patients of any age receiving dialysis treatment. Patients receiving
long-acting ESAs or included in studies comparing shorter with
longer acting ESAs were excluded. Kidney transplant recipients
were also excluded.
Types of interventions• Short-acting ESAs including epoetins alpha (Eprex®, Procrit®,
Epogen®), beta (Recormin®), delta (Dynepo®), epoetin theta
(Biopoin®) and biosimilars of epoetin alpha (HX575, EPO- hexal®,
Abseamed®), epoetin zeta (Silapo®, Retacrit®, Epoetin Hospira®)• Short-acting ESAs including epoetins with diCerent routes of
administration• Short-acting ESAs including epoetins used at diCerent
frequencies of administration• Short-acting ESAs including epoetins used at diCerent doses• Head-to-head comparisons of diCerent short-acting ESAs.
Types of outcome measures
Primary outcomes
1. Death• All-cause mortality• Mortality due to cardiac disease or cerebrovascular events
2. Measures of correction of anaemia• Values of Hb/HCT or change in Hb/HCT at the end of the study
3. Quality of life.
Secondary outcomes
1. Hypertension and blood pressure outcomes• Hypertension (number of patients presenting one or more
episodes of hypertension)• Systolic blood pressure at end of treatment (mm Hg)• Diastolic blood pressure at end of treatment (mm Hg).
2. Cardiovascular morbidity
3. Cerebrovascular morbidity
4. Adverse eCects• Number needing blood transfusion• Thrombotic events• Number ceasing ESA for adverse eCects• Number of patients requiring hospitalisations for any cause• Number of patients developing antibody-mediated pure red
cell aplasia• Number of patients developing a malignancy.
5. Kidney function measures (GFR, serum creatinine (SCr),
doubling of SCr) as reported by the authors of primary studies
6. Need for iron supplementation.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Kidney and Transplant Specialised
Register up to 12 September 2016 through contact with the
Information Specialist using search terms relevant to this review.
The Specialised Register contains studies identified from several
sources.
Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients (Review)
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1. Monthly searches of the Cochrane Central Register of Controlled
Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney-related journals and the proceedings
of major kidney conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney journals
6. Searches of the International Clinical Trials Register (ICTRP)
Search Portal and ClinicalTrials.gov.
Studies contained in the Specialised Register were identified
through search strategies for CENTRAL, MEDLINE, and EMBASE
based on the scope of Cochrane Kidney and Transplant. Details
of these strategies, as well as a list of handsearched journals,
conference proceedings and current awareness alerts, are available
in the Specialised Register section of information about Cochrane
Kidney and Transplant.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of review articles, relevant studies and clinical
practice guidelines.
2. Letters seeking information about unpublished or incomplete
studies to investigators known to be involved in previous
studies.
Data collection and analysis
Selection of studies
The search strategy described was used to obtain titles and
abstracts of studies that may be relevant to the review. The titles
and abstracts were screened independently by two authors, who
discarded studies that were not applicable; however studies and
reviews that might have included relevant data or information
on studies were retained initially. Two authors independently
assessed the retrieved abstracts and, if necessary the full text, of
these studies to determine which studies satisfied the inclusion
criteria.
Data extraction and management
Data extraction was carried out independently by at least two
authors using standard data extraction forms. Where there was
more than one publication of a study, reports were grouped
together and the publication with the most complete data was used
in the analyses. Where relevant outcomes were only published in
earlier versions these data were used. Any discrepancy between
published versions was highlighted.
Assessment of risk of bias in included studies
The following items were independently assessed by two authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2).
• Was there adequate sequence generation (selection bias)?• Was allocation adequately concealed (selection bias)?• Was knowledge of the allocated interventions adequately
prevented during the study?* Participants and personnel (performance bias)* Outcome assessors (detection bias)
• Were incomplete outcome data adequately addressed (attrition
bias)?• Were reports of the study free of suggestion of selective outcome
reporting (reporting bias)?• Was the study apparently free of other problems that could put
it at a risk of bias?
Measures of treatment e:ect
For dichotomous outcomes (e.g. all-cause mortality, adverse
events, number needing transfusions) results were expressed as
risk ratio (RR) with 95% confidence intervals (CI). Where continuous
scales of measurement were used to assess the eCects of treatment
(e.g. final Hb/HCT or change in Hb/HCT, blood pressure, SCr),
the mean diCerence (MD) was used, or the standardised mean
diCerence (SMD) if diCerent scales had been used.
Unit of analysis issues
We included only data from the first period of treatment in cross-
over studies (Higgins 2011). Data expressed in diCerent metrics
were analysed using SMD.
Dealing with missing data
Any further information required from the original author was
requested by written correspondence (e.g. emailing corresponding
authors) and any relevant information obtained in this manner
was included in the review. We aimed to analyse available data in
meta-analyses using intention-to-treat (ITT) data. However, where
only ITT data were available graphically or were not provided
and additional information could not be obtained from the study
authors, per-protocol (PP) data was used in analyses.
We imputed a change-from-baseline standard deviation using
an imputed correlation coeCicient when suCicient data were
available.
Assessment of heterogeneity
Heterogeneity was analysed using a Chi2 test on N-1 degrees of
freedom, with an alpha of 0.05 used for statistical significance and
with the I2 test (Higgins 2003). I2 values of 25%, 50% and 75%
correspond to low, medium and high levels of heterogeneity.
Assessment of reporting biases
The search strategy applied aimed to reduce publication bias
caused by lack of publication of studies with negative results. We
investigated for publication bias using funnel plots if there were
suCicient studies of each comparison (Higgins 2011).
Data synthesis
Data were summarised using the random-eCects model but the
fixed-eCect model was also used to ensure robustness of the model
chosen. We qualitatively summarised data where insuCicient data
were available for meta-analysis. Where there were multiple
publications of the same study, all reports were reviewed to
ensure that all details of methods and results were included.
Qualitative review was conducted for adverse events and quality of
life outcomes.
Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients (Review)
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Subgroup analysis and investigation of heterogeneity
Subgroup analysis was used to explore possible sources of
heterogeneity (participants, interventions and study quality).
Heterogeneity among participants could be related to age (adult
versus children) or stage of CKD. Heterogeneity in interventions
could be related to dose, duration or frequency of rHuEPO
treatment or to the route of administration. . Where possible, the
risk ratio with 95% CI was calculated for each adverse eCect, either
compared to no treatment or to another agent.
Sensitivity analysis
Sensitivity analyses tested decisions where inclusion of a study
may have altered the results of the meta-analysis. In particular,
sensitivity analysis may be used to test decisions where ITT and PP
data were included in the same analyses.
'Summary of findings' tables
We presented the main results of the review in 'Summary of
findings' tables. These tables present key information concerning
the quality of the evidence, the magnitude of the eCects of
the interventions examined, and the sum of the available data
for the main outcomes (Schünemann 2011a). The 'Summary of
findings' tables also include an overall grading of the evidence
related to each of the main outcomes using the GRADE (Grades
of Recommendation, Assessment, Development and Evaluation)
approach (GRADE 2008). The GRADE approach defines the quality
of a body of evidence as the extent to which one can be confident
that an estimate of eCect or association is close to the true quantity
of specific interest. The quality of a body of evidence involves
consideration of within-trial risk of bias (methodological quality),
directness of evidence, heterogeneity, precision of eCect estimates
and risk of publication bias (Schünemann 2011b). We presented the
following outcomes in the 'Summary of findings' tables.
• Epoetin alpha every 2 weeks compared to weekly for anaemia in
CKD patients not receiving dialysis (Summary of findings for the
main comparison)* Final or change in Hb level (g/dL)
* Number reaching target Hb* Number of deaths* Number with adverse events: red blood cell transfusions,
hypertension, thrombovascular events• Epoetin alfa every four weeks compared with every two weeks
in CKD patients not receiving dialysis (Summary of findings 2)* Final or change in Hb level (g/dL)* Number reaching target Hb* Number of deaths* Number with adverse events: red blood cell transfusions,
hypertension, thrombovascular events• Epoetin theta versus epoetin beta (Summary of findings 3)* Final Hb (g/dL)* Mean weekly epoetin dose (U/kg)* Number of deaths* Number with adverse events: hypertension, red blood cell
transfusions, discontinuation of therapy.
R E S U L T S
Description of studies
Results of the search
Seventy-three reports were identified from the search to 12
September 2016. AMer title and abstract screening 22 reports were
excluded. Full-text review was carried out the remaining 51 reports.
Fourteen studies (30 reports) (Aggarwal 2002; Akiba 1992; Amon
1992; Frenken 1989; Gertz 2012; Haag-Weber 2012; Knebel 2008;
Kronborg 1994; Mignon 2000; Pergola 2009; Pergola 2010; PROMPT
Study 2005; Sohmiya 1998; Spinowitz 2008) were included and
17 studies (19 reports) (Brown 1988; Clyne 1992; Duliege 2005;
Furukawa 1992; Li 2004; Meloni 2003; NCT00240734; NCT00492427;
NCT00563355; Patel 2012; Schwartz 1989; Shaheen 1983; Singh
1999; Teehan 1990; Teplan 1995; Yamazaki 1993; Zheng 1992)
were excluded. Two recently completed studies (NCT01576341;
NCT01693029) will be assessed in a future update of this review
(Figure 1).
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Figure 1.   Study flow diagram.
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Included studies
The 14 studies were divided into four treatment comparisons
groups (Figure 1).
Epoetin alpha or beta administered at dierent frequencies
using the same total dose
Six studies (Amon 1992; Pergola 2009; Pergola 2010; PROMPT
Study 2005; Sohmiya 1998; Spinowitz 2008) (1613 enrolled/1585
evaluated participants) compared epoetin alpha or beta at diCerent
frequencies using the same total dose in each group.
• Four studies (Pergola 2009; Pergola 2010; PROMPT Study 2005;
Spinowitz 2008) with 840 enrolled (838 analysed) participants
compared epoetin alpha administered at 10,000IU per week
with 20,000IU given every two weeks.• Three studies (Pergola 2010; PROMPT Study 2005; Spinowitz
2008) with 724 analysed participants also compared epoetin
alpha administered at 20,000 IU every two weeks with 40,000 IU
every four weeks.• Amon 1992 (22 enrolled, 18 evaluated) compared subcutaneous
epoetin alpha 50 IU/kg three times a week with 150 IU/kg given
once weekly in children.• Sohmiya 1998 (5 enrolled, 5 evaluated) compared continuous
infusion of epoetin beta with weekly subcutaneous injections for
four weeks using the same total dose in each group in a cross
over study.
Epoetin alpha administered at the same frequency using
dierent total doses
Three studies (Akiba 1992; Frenken 1989; Spinowitz 2008) (339
enrolled/333 analysed participants) compared epoetin alpha at
diCerent doses but at the same frequencies.
• Spinowitz 2008 (150 enrolled/144 evaluated) compared 20,000
IU given four weekly with 40 000IU given four weekly• Akiba 1992 (165 enrolled and evaluated) compared 3000 IU, 6000
IU and 12 000 IU given weekly to three groups• Frenken 1989 (24 enrolled and evaluated) compared 50 IU/Kg,
100 IU/kg and 150 IU/Kg given three times weekly.
Epoetin alpha intravenous versus subcutaneous administration• Aggarwal 2002 (20 participants enrolled and evaluated)
compared subcutaneous with intravenous administration of
epoetin alpha.
Epoetin alpha or beta versus other epoetins or biosimilars of
epoetin alpha
Five studies Gertz 2012; Haag-Weber 2012; Knebel 2008;Kronborg
1994; Mignon 2000) (794 participants) were included in this
comparison.
• Gertz 2012 (288 enrolled and evaluated) compared weekly
subcutaneous epoetin theta with epoetin beta• Haag-Weber 2012 (337 enrolled) compared a bio-similar HX575
epoetin alpha with epoetin alpha (Eprex). This study was
terminated due to the development of neutralising antibodies in
two patients receiving subcutaneous HX575. ECicacy could not
be assessed because the authors did not provide the number
of patients, who contributed data to eCicacy endpoints. Limited
safety data were available.• Two studies (Mignon 2000, Knebel 2008) (140 enrolled)
compared subcutaneous administration of epoetin delta with
epoetin alpha. Both studies were terminated before completion
when the pharmaceutical company ceased production of
epoetin delta for commercial reasons and no data were
available.• Kronborg 1994 (29 enrolled and evaluated) compared pain
scores in participants treated with epoetin alpha or epoetin beta
given subcutaneously using a visual analogue scale (VAS) and a
verbal descriptive scale (VDS). As the results included a median
with inter-quartile ranges the data could not be included in a
meta-analysis.
Excluded studies
Seventeen studies were excluded. Eleven studies were ineligible
as they compared a short-acting ESA with placebo or no
treatment (Brown 1988; Clyne 1992; Meloni 2003; NCT00240734;
NCT00563355; Patel 2012; Schwartz 1989; Shaheen 1983; Singh
1999; Teehan 1990; Teplan 1995). NCT00492427 compared short-
acting ESA with the long acting ESA, darbepoetin and this study is
included in another review (Palmer 2014b). Three studies assessed
other interventions, or were pharmacokinetic studies (Duliege
2005; Furukawa 1992; Li 2004). Randomisation was unclear in two
studies (Yamazaki 1993; Zheng 1992).
Risk of bias in included studies
The results of the risk of bias assessment are shown in Figure 2 and
Figure 3.
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Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 3.   (Continued)
 
Allocation
Sequence generation was deemed at low risk of bias in three
studies (Gertz 2012; PROMPT Study 2005; Spinowitz 2008) and
unclear in the remaining eleven studies (Aggarwal 2002; Akiba
1992; Amon 1992; Frenken 1989; Haag-Weber 2012; Knebel 2008;
Kronborg 1994; Mignon 2000; Pergola 2009; Pergola 2010; Sohmiya
1998).
Allocation concealment was at low risk of bias in two studies (Gertz
2012; Spinowitz 2008) and unclear in the remaining twelve studies
(Aggarwal 2002; Akiba 1992; Amon 1992; Frenken 1989; Haag-Weber
2012; Knebel 2008; Kronborg 1994; Mignon 2000; Pergola 2009;
Pergola 2010; PROMPT Study 2005; Sohmiya 1998).
Blinding
Only one study (Gertz 2012) was blinded and considered to be at
low risk of bias for performance bias. Ten studies were not blinded
and determined as high risk of performance bias (Aggarwal 2002;
Amon 1992; Frenken 1989; Haag-Weber 2012; Knebel 2008; Pergola
2009; Pergola 2010; PROMPT Study 2005; Sohmiya 1998; Spinowitz
2008). Blinding was unclear in the remaining three studies (Akiba
1992; Kronborg 1994; Mignon 2000).
As the primary outcomes (final Hb level or change in Hb level) in
all studies were based on laboratory assessment, and therefore
unlikely to be influenced by blinding, 13 studies were deemed to
be at low risk of detection bias. The study by Kronborg 1994 was
considered at unclear risk of detection bias; it assessed pain scores
and was said to be double-blinded though no information was
provided as to how this was performed.
Incomplete outcome data
Eight studies were determined to be at low risk of attrition bias
(Aggarwal 2002; Gertz 2012; Kronborg 1994; Pergola 2009; Pergola
2010; PROMPT Study 2005; Sohmiya 1998; Spinowitz 2008). Four
studies were at high risk of bias because meta-analyses could not
be performed as total patient numbers were not provided (Akiba
1992; Haag-Weber 2012; Knebel 2008) or because more than 10%
patients were excluded from analysis (Amon 1992). Attrition bias
was deemed unclear in the remaining two studies (Frenken 1989;
Mignon 2000).
Selective reporting
Studies that did not provide data on final or change in Hb and on
patient-centred outcomes including adverse events such as blood
transfusions, vascular access complications or all-cause mortality
were considered to be at high risk for selective reporting. Eight
studies were considered at high risk of reporting bias (Aggarwal
2002; Akiba 1992; Amon 1992; Haag-Weber 2012; Knebel 2008;
Kronborg 1994; Mignon 2000; Sohmiya 1998). Six studies (Amon
1992; Gertz 2012; Pergola 2009; Pergola 2010; PROMPT Study 2005;
Spinowitz 2008) were assessed at low risk for selective reporting.
Other potential sources of bias
Only two studies were assessed at free of other potential bias
sources (Frenken 1989; Sohmiya 1998). Eight studies were industry
funded and determined as at high risk of bias (Gertz 2012; Haag-
Weber 2012; Knebel 2008; Mignon 2000; Pergola 2009; Pergola 2010;
PROMPT Study 2005; Spinowitz 2008). In the remaining four studies
it was unclear whether the study was free of other potential sources
of bias (Aggarwal 2002; Akiba 1992; Amon 1992; Kronborg 1994).
E:ects of interventions
See: Summary of findings for the main comparison Epoetin alpha
every 2 weeks versus to weekly for anaemia in CKD patients not
receiving dialysis; Summary of findings 2 Epoetin alfa every four
weeks versus with every two weeks in CKD patients not receiving
dialysis; Summary of findings 3 Epoetin theta versus epoetin beta
in CKD patients not receiving dialysis
Epoetin alpha administered at di:erent frequencies using the
same total dose
Six studies investigated this comparison (Amon 1992; Pergola 2009;
Pergola 2010; PROMPT Study 2005; Sohmiya 1998; Spinowitz 2008).
Epoetin alpha weekly versus every two weeks using same total
dose of epoetin
In meta-analyses of four non-inferiority studies (Pergola 2009;
Pergola 2010; PROMPT Study 2005; Spinowitz 2008), final Hb levels
(Analysis 1.1 (4 studies, 785 participants): MD -0.20 g/dL, 95% CI
-0.33 to -0.07) and the number achieving target Hb were statistically
significantly higher in patients receiving weekly doses compared
with two weekly doses (Analysis 1.2 (4 studies, 798 participants): RR
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0.96, 95% CI 0.93 to 0.99). The diCerences were not considered to
be clinically significant. No significant heterogeneity was noted.
There were no significant diCerence in all-cause mortality (Analysis
1.3 (4 studies, 838 participants): RR 0.89, 95% CI 0.38 to 2.07),
the number requiring transfusion (Analysis 1.4.1 (3 studies, 580
participants): RR 1.56, 95% CI 0.71 to 3.45), the number with
hypertension (Analysis 1.4.2 (4 studies, 838 participants): RR
0.85, 95% CI 0.55 to 1.32), the number with thrombovascular
complications Analysis 1.4.3 (4 studies, 838 participants): RR 1.41,
95% CI 0.67 to 3.00) or the number discontinuing therapy due to
adverse eCects (Analysis 1.4.4 (1 study, 258 participants): RR 0.98,
95% CI 0.20 to 4.79).
No neutralising antibodies were detected in study participants
in Pergola 2009 and Pergola 2010. Most of the deaths were
due to cardiovascular complications reflecting the underlying
cardiovascular morbidity of the population studied. Only one study
(PROMPT Study 2005) performed quality of life (QOL) assessments
and reported no statistical diCerences in the final QOL scores
between groups receiving epoetin once weekly or two weekly.
Epoetin alpha every two weeks versus every four weeks using
same total dose of epoetin
In meta-analyses of three non-inferiority studies (Pergola 2010;
PROMPT Study 2005; Spinowitz 2008), there were no significant
diCerences in final Hb levels (Analysis 2.1 (3 studies, 671
participants): MD -0.16 g/dL, 95% CI -0.43 to 0.10; I2 = 63%) or in
the number reaching target Hb levels (Analysis 2.2 (3 studies, 687
participants): RR 0.95, 95% CI 0.84 to 1.07) with dosing every two
weeks compared with every four weeks. There was unexplained
marked heterogeneity between these studies.
There were no significant diCerences in all-cause mortality
(Analysis 2.3 (3 studies, 724 participants): RR 0.95, 95% CI 0.33 to
2.75), the number requiring transfusions (Analysis 2.4.I (2 studies,
470 participants): RR 1.26, 95% CI 0.53 to 2.98); the number
with hypertension (Analysis 2.4.2 (3 studies, 724 participants): RR
1.02, 95% CI 0.62 to 1.69); and the number with thrombovascular
complications (Analysis 2.4.3 (3 studies, 724 participants): RR 1.02,
95% CI 0.39 to 2.68). PROMPT Study 2005 noted no diCerence in
final QOL scores between participants who received epoetins at two
weekly or four weekly intervals.
Other studies
Amon 1992 found that the time to reach a Hb level greater than
11.5 g/dL were significantly longer with weekly administration (15.6
weeks) compared with thrice weekly administration (9.3 weeks).
Adverse eCects were uncommon and did not diCer between groups
and there was no deterioration in glomerular filtration rate across
the two groups. However there was no significant diCerence in
mean dose/week to sustain Hb levels between diCerent frequencies
of administration.
Sohmiya 1998 in a cross-over study found that continuous
subcutaneous infusion of epoetin beta resulted in a significantly
greater increase in Hb levels compared with weekly subcutaneous
injections (2.56 ± 0.77 g/dL versus 0.28 ± 0.62 g/dL, P < 0.05)
Epoetin alpha administered at same frequency using di:erent
total doses
Three studies reported on this comparison (Akiba 1992; Frenken
1989; Spinowitz 2008)
Epoetin alpha dierent doses given three times weekly
Frenken 1989 reported no statistical significance in the final Hb
in groups which received 100 IU/kg/dose (Analysis 3.1.1 (1 study,
16 participants): MD 0.70 g/dL, 95% CI -0.78 to 2.18) or 150 IU/
kg/dose (Analysis 3.1.2 (1 study, 16 participants): MD 1.00 g/
dL, 95% CI -0.18 to 2.18) compared with 50 IU/kg/dose. Final
mean arterial blood pressures and serum creatinine levels did
not diCer between subgroups (Analysis 3.2; Analysis 3.3). No anti-
erythropoietin antibodies were detected in the study participants.
The study reported overall improvement in well-being in all
participants receiving epoetin.
Epoetin alpha dierent doses given every four weeks
Spinowitz 2008 reported no significant diCerence in the final Hb
level (Analysis 4.1 (1 study, 144 participants): MD 0.17 g/dL 95%
CI -0.19 to 0.53) and the number reaching target Hb (Analysis 4.2
(1 study, 144 participants): RR 1.07, 95% CI 0.92 to 1.24) when
epoetin alpha was administered at 20,000 U compared with 40,000
U every four weeks. There was no significant diCerence in all-cause
mortality (Analysis 4.3.1), the number with hypertension (Analysis
4.4.1), thrombovascular complications (Analysis 4.4.2) or number
of patients requiring transfusions (Analysis 4.4.3).
Epoetin alpha dierent doses given every week
Akiba 1992 reported that 6000 IU and 12,000 IU given weekly
increased HCT levels more than 3000 IU/week. No standard
deviations were provided.
Epoetin alpha intravenous versus subcutaneous
administration
Aggarwal 2002 reported no significant diCerence in final Hb at 12
weeks (Analysis 5.1 (20 participants): MD -0.99 g/dL, 95% CI -2.08
to 0.10) between intravenous and subcutaneous administration of
epoetin alpha.
Epoetin alpha versus other epoetins or biosimilars
Five studies compared epoetin alpha with other epoetins or
biosimilars.
Gertz 2012 found no significant diCerences in final Hb (Analysis
6.1 (288 participants): MD -0.02 g/dL, 95% CI -0.25 to 0.21) and
weekly epoetin doses (Analysis 6.2 (288 participants) MD 0.40
U/kg, 95% CI -5.68 to 6.48) between epoetin theta and epoetin
beta. No significant diCerences were noted in all-cause mortality
(Analysis 6.3 (288 participants): RR 2.46, 95% CI 0.29 to 20.77),
hypertension (Analysis 6.4.1 (288 participants): RR 0.35, 95% CI 0.11
to 1.08); transfusions (Analysis 6.4.2 (288 participants): RR 1.48,
95% CI 0.06 to 36.10) and discontinuation of therapy (Analysis 6.4.3
(288 participants): RR 1.77, 95% CI 0.68 to 4.63). No neutralising
antibodies were noted in either intervention group. Most of the
deaths were due to cardiovascular complications reflecting the
population studied.
The quality of this single study was assessed as moderate for
the surrogate outcome of final Hb but as low for mean weekly
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epoetin dose because of imprecision (Summary of findings 3). The
quality of evidence for patient-centred outcomes was assessed
as low for all-cause mortality, need for blood transfusion and
discontinuation of medications and moderate for hypertension
because of imprecision due to small numbers of events
Haag-Weber 2012 (337 participants) compared the biosimilar
HX575 epoetin alpha with epoetin alpha; both medications were
administered subcutaneously. The study was ceased when two
patients receiving HX575 developed antibodies to epoetin and
pure red cell aplasia and HX575 epoetin alpha was withdrawn for
subcutaneous administration. The change in Hb from baseline at 13
weeks did not diCer between groups (HX575 2.2 ± 0.9 g/dL; epoetin
alpha 2.2 ± 1.0 g/dL) but the data could not be included in meta-
analyses since no denominators were provided and information
could not be obtained from the authors.
Mignon 2000 (65 participants) found no significant diCerences in
response between epoetin delta and epoetin alpha when both
were given at the same dose (50 IU/kg/wk). Adverse events were
similar between epoetin delta and epoetin alpha. No data were
available from Knebel 2008 (60 participants). Since epoetin delta
production was ceased for commercial reasons and no information
could be obtained from the pharmaceutical company, no meta-
analyses were performed.
Kronborg 1994 (29 participants) found that pain scores were higher
in participants treated with subcutaneous epoetin alpha compared
with epoetin beta. The results were provided as median with inter-
quartile ranges so could not be included in a meta-analysis.
Other outcomes
From the available studies, we were not able to analyse the
outcomes of causes of death, cardiovascular and cerebrovascular
morbidity, kidney function, number of hospitalisations, additional
requirement for IV iron, serious infections, or de novo malignancies.
D I S C U S S I O N
Summary of main results
Fourteen studies (30 reports) with 2616 participants were included
in this review, which evaluated the eCicacy and safety of short-
acting ESAs in CKD patients, not requiring dialysis.
Six studies (1613 enrolled participants) compared epoetin alpha
or epoetin beta at diCerent frequencies using the same total
dose in each group, with two studies having insuCicient data for
inclusion in meta-analyses. Among four studies, no significant
diCerences in end of study Hb, in the number of participants
achieving target Hb, in all-cause mortality or in adverse eCects
were identified when dosing every two weeks was compared with
weekly dosing or when four weekly dosing was compared with two
weekly dosing. These data suggest that larger doses of short-acting
epoetins given less frequently can be administered to CKD patients
not requiring dialysis without a loss of eCicacy or an increase in
adverse eCects. However this conclusion is based on low quality
evidence (Summary of findings for the main comparison; Summary
of findings 2). Three studies (including Spinowitz 2008, in which
diCerent frequencies were also evaluated) compared diCerent total
doses of epoetin alpha given at the same frequency though data
from only two studies could be included in meta-analyses. Both
studies found no significant diCerence in final Hb or adverse eCects
with diCerent total doses.
The remaining five studies evaluated diCerent interventions. One
study (288 participants) compared epoetin theta with epoetin
alpha and found no significant diCerences in eCicacy or adverse
eCects. Two studies (125 participants) compared epoetin delta
with epoetin alpha. However no results were available since the
pharmaceutical company withdrew epoetin delta for commercial
reasons. The fourth study was terminated before completion aMer
two patients receiving the biosimilar epoetin, HX575 epoetin alpha,
developed anti-epoetin antibodies and pure red cell aplasia. The
fiMh study found significantly higher pain scores with subcutaneous
epoetin alpha compared with epoetin beta.
Overall completeness and applicability of evidence
For this review we were only able to identify 14 studies (2616
participants), which evaluated diCerent frequencies, doses or
routes of administration of the same epoetins or compared
diCerent epoetins in pre-dialysis patients. Only seven studies
contributed data to meta-analyses with two of these studies
enrolling only 20 and 24 patients respectively. Two studies
evaluated children and neither had suCicient data for inclusion
in meta-analyses. Two studies were terminated before completion
without available data when the pharmaceutical company ceased
production of epoetin delta for commercial reasons. One study
was terminated when two patients developed antibody mediated
pure red cell aplasia with HX575 epoetin alpha, a biosimilar
epoetin. No studies in pre-dialysis patients were identified,
which evaluated HX575 epoetin alpha, given intravenously, or
of SB309 (epoetin zeta) given intravenously or subcutaneously.
These biosimilar epoetins are approved for use by the European
Medicines Agency. Preliminary information indicates that SB309
(epoetin zeta, Epoetin Hospira®) has not been approved for use in
the USA (Big Molecule Watch Blog 2015).
Patient-centred outcomes were generally poorly reported. Only
one study reported on a quality of life assessment with no
diCerences identified in end of study quality of life scores between
diCerent frequencies of epoetin alpha administration (PROMPT
Study 2005). Six studies reported on all-cause mortality. Data on
hypertension and thrombovascular events, adverse eCects known
to be associated with epoetin administration, could be included
in meta-analyses from only five studies. Data from four studies on
the number of participants, requiring blood transfusions, could be
included in meta-analyses. Anti-erythropoietin antibodies, which
can cause pure red cell aplasia, were assessed In only five studies.
Quality of the evidence
Of the fourteen studies included in this review, four studies were
available in abstract format only.
Only three of 14 studies demonstrated adequate random sequence
generation, with only two studies assessed as showing low risk
of bias for allocation concealment. Blinding of participants and
personnel was at low risk of bias in one study only. Blinding of
outcome assessment was judged at low risk in 13 studies as the
outcome measures were laboratory based. Attrition and reporting
bias were at low risk of bias in eight and seven studies respectively
(Figure 3).
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Only five of 14 studies could be included in the Summary of Findings
tables as other comparisons included single small studies only or
data which could not be included in the meta-analyses. Overall
the quality of the studies (GRADE 2011a; GRADE 2011b) included in
meta-analyses was assessed as low indicating that our confidence
in the results is significantly reduced because of poor study quality
and the use of surrogate outcomes as the primary outcomes of the
included studies.
The quality of the studies included in meta-analyses comparing
epoetin alpha every two weeks with weekly administration
(Summary of findings for the main comparison) and in meta-
analyses comparing epoetin alpha every four weeks with two
weekly administration (Summary of findings 2) for the eCicacy
outcomes of change in Hb level and number reaching target Hb
were assessed as low or very low. These were down-graded for
indirectness on the GRADE profile, since these were surrogate
outcomes and not patient-centred outcomes. In the comparison
of epoetin alpha given every four weeks compared with every two
weeks, the results were further downgraded because of marked
unexplained heterogeneity. In addition the quality of the evidence
for eCicacy was downgraded because of poor study design and/
or reporting particularly of sequence generation and allocation
concealment and for imprecision, where small numbers of events
resulted in wide confidence intervals. Outcomes for adverse eCects
were downgraded because of poor study design and imprecision.
The quality of the single study included in meta-analyses
comparing epoetin theta with epoetin beta was assessed as
moderate for the surrogate outcome of final Hb but as low for mean
weekly epoetin dose because of imprecision (Summary of findings
3). The quality of evidence for patient-centred outcomes was
assessed as low for all-cause mortality, need for blood transfusion
and discontinuation of medications and moderate for hypertension
because of imprecision due to small numbers of events.
Potential biases in the review process
For this review a comprehensive search of the Cochrane Kidney and
Transplant's Specialised Register was performed, which reduced
the likelihood that eligible published studies were omitted from
the review. Eligible studies published aMer the last search date
of 12 September 2016 or published in congress proceedings not
routinely searched could have been missed. Four studies were only
available in abstract form which provided limited information on
study methods and results. Inclusion of these studies could be a
source of bias.
The review was completed independently by at least three authors,
who participated in all steps of the review. This limited the risk of
errors in determining study eligibility, data extraction, risk of bias
assessment and data synthesis.
Many of the earlier epoetin alpha studies were small with
incomplete information on study methods and results. Further
information could not be obtained about these studies from
investigators or the literature.
Although six of the included studies were sponsored by
pharmaceutical companies, these were multi-centre studies and
so were able to attract larger patient numbers. In two of these
studies per-protocol data were included in meta-analyses for the
primary outcomes of final Hb or change in Hb, since ITT data were
only presented graphically. In both studies the authors reported
that sensitivity analyses using ITT populations were consistent
with those from the per-protocol populations, thus increasing
confidence in the findings.
Agreements and disagreements with other studies or
reviews
No evidence was identified by the KDIGO working group to
suggest that any given type of ESA was superior to another in
terms of eCicacy and safety (KDIGO 2012). The Working Group
suggested ESA choice was dependent on patient and country
specific issues including availability, cost and treatment setting.
The NICE guidelines 2015 (NICE 2015) suggest the choice of ESA
should be discussed with the patient with anaemia and CKD when
initiating the patient on treatment, taking into consideration the
route of administration and the local availability of ESA. There is
no evidence to distinguish between ESAs in term of eCicacy. The
findings of this systematic review confirm these recommendations.
The findings of this review complement other Cochrane Kidney
and Transplant reviews of ESA including an updated review
comparing epoetin in pre-dialysis patients with placebo or no
specific treatment (Cody 2016), a review evaluating the benefits
and harms of diCerent Hb or HCT targets in CKD patients receiving
ESA treatment for anaemia (Strippoli 2006), a review evaluating
darbepoetin (Palmer 2014b) and a network meta-analysis of studies
of any ESA formulation (Palmer 2014a). While ESAs clearly reduce
the need for blood transfusion, no systematic review to date has
found clear evidence for the superiority of any ESA formulation over
any other formulation based on available eCicacy and safety data.
For consumers, clinicians and funders, considerations such as drug
cost, availability and preferences for dosing frequency should be
considered as the basis for individualising anaemia care due to
lack of data for comparative diCerences in the clinical benefits and
harms of diCerent ESA preparations.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
A previous review identified that epoetin alpha was eCective
compared with placebo or no treatment in raising Hb levels without
a significant reduction in GFR in patients with CKD not on dialysis
(Cody 2016). Our review extends these observations to show that
epoetin alpha given at higher doses for extended intervals is non-
inferior to more frequent dosing intervals. The benefits oCered by
the extended dosing intervals include convenience for the patients
and healthcare providers and may also result in cost eCiciency. This
may be of benefit in countries with more limited resources and
access to longer acting more costly ESAs. However the data are
of low quality so that diCerences in eCicacy and adverse eCects
cannot be completely excluded. We did not identify any studies
which evaluated diCerent frequencies of epoetin beta. In a single
study, epoetin theta did not diCer significantly from epoetin beta in
haematological outcomes or adverse eCects.
We only identified one study in predialysis patients comparing
a biosimilar preparation of epoetin alpha (HX575 epoetin alpha,
Binocrit®) in non-dialysis patients and this study was terminated
because of the development of pure red cell aplasia with
neutralising antibodies (Haag-Weber 2012). HX575 epoetin alpha
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and a second biosimilar of epoetin alpha (epoetin zeta, Retacrit®)
received marketing authorization throughout the European Union
in 2007; HX575 epoetin alpha is limited to intravenous use.
Because the safety record of these compounds is limited
compared with epoetin alpha and epoetin beta, the ERBP Work
Group recommends stringent pharmacovigilance for biosimilars
of epoetin alpha (ERBP 2009). Two clinical studies evaluating the
biosimilar HX575 epoetin alpha in the USA have been completed
(NCT01693029a, NCT01576341a) but the results are not yet
available. Of these one (NCT01576341a) evaluated subcutaneous
administration of HX575 epoetin alpha in predialysis patients in
a single arm study aiming to determine eCicacy, adverse eCects
and the incidence of anti-epoetin antibodies. The uptake in the
nephrology community of the biosimilar ESAs will ultimately
depend on the balance between cost savings and residual concerns
regarding safety (Mikhail 2013; Schellekens 2009).
Implications for research
As noted in earlier ESA reviews (Hahn 2014; Strippoli 2006) the
reporting of treatment eCects of ESAs on potentially important
patient outcomes is heterogeneous and poor, thereby limiting a
good understanding of how ESA therapy aCects the way patients
feel and function. Currently decisions regarding diCerent agents in
clinical practice are dictated by physician and patient preference,
drug cost and availability since we have inconclusive evidence of
the eCects of diCerent short-acting ESAs or of diCerent frequencies
of ESA administration on survival and quality of life. Data regarding
eCectiveness and safety when treating children with ESAs remains
limited.
Therefore additional large, well designed, randomised studies are
required in the following areas to compare larger doses of the
shorter acting ESAs including new biosimilars of epoetin alpha
administered less frequently with more frequent dosing in both
children and adults with CKD not on dialysis. These studies
should include patient-centred outcomes including all-cause
mortality, cardiovascular mortality and morbidity, and quality
of life assessment. Estimates of patient and carer satisfaction
related to diCerent frequencies of administration should be
included. Studies of cost-eCectiveness of diCerent frequencies of
administration should also be undertaken.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods • Study design: RCT• Study duration: not reported• Duration of follow-up: 3 months
Participants • Country: India• Setting: Single centre, Nephrology outpatient clinic• Adults, pre-dialysis (SCr ≥ 2 mg/dL), anaemia (Hb 5 to 8 g/dL)• Number: 20• Mean age ± SD (years): treatment group 1 (43.2 ± 16.1); treatment group 2 (47.32 ± 20.4)• Sex (M/F): 12/8• Exclusion criteria: uncontrolled hypertension; coronary artery disease; chronic infections; chronic
bleeding; androgen therapy
Interventions Treatment group 1
• Epoetin alpha: 2000 IU SC in 1 mL pre-filled syringe 3 times/week for 4 weeks then twice weekly for 1
month then fortnightly for 1 month
Treatment group 2
• Epoetin alpha: 2000 IU IV in 1 mL pre-filled syringe 3 times/week for 4 weeks then twice weekly for 1
month then fortnightly for 1 month
Co-interventions
• Ferrous sulphate: 200 mg twice daily• Folic acid: daily
Outcomes • Hb level at 12 weeks
Notes • Funding source: not reported
Aggarwal 2002 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Lack of blinding could influence patient management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory based outcome and unlikely to be influenced by blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients included in assessment
Selective reporting (re-
porting bias)
High risk No information on adverse effects
Other bias Unclear risk Insufficient information to permit judgement
Aggarwal 2002  (Continued)
 
 
Methods • Study design: RCT• Study duration: 8 weeks• Duration of follow-up: not reported
Participants • Country: Japan• Setting: multicentre• Pre-dialysis, uraemic, adults• Number: 165• Mean age (range): not reported• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment groups
• Epoetin alpha dose given once weekly SC* 3000 (L)* 6000 (M)* 12,000 (H)
Outcomes • HCT at 8 weeks• Adverse effects: hypertension• Changes in BUN and SCr and slope
Notes • Abstract only
Akiba 1992 
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• Aggravations in blood pressure noted in one case in L, two in M, and 3 in H• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Said to be double blind, though insufficient information to permit judgement
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory outcome and blinding unlikely to influence
Incomplete outcome data
(attrition bias) 
All outcomes
High risk No patient denominators supplied
Selective reporting (re-
porting bias)
High risk Insufficient information to permit judgement (abstract only), however no full
text publication by December 2016
Other bias Unclear risk Insufficient information to permit judgement
Akiba 1992  (Continued)
 
 
Methods • Study design: RCT• Study duration: not reported• Duration of follow-up: not reported
Participants • Country: Germany• Setting: multicentre• Children with CKD not on dialysis• Number: 22 (evaluated 18)• Mean age (range): 6.2 years (0.3 to 17 years)• Sex (M/F): not reported• Exclusion criteria: not reported
Interventions Treatment group 1
• Epoetin alpha SC: 50 IU/kg 3 times/week
Treatment group 2
• Epoetin alpha SC: 150 IU/kg once/week
Outcomes • Response interval (time to increase in Hb of 2 g/dL)• Change in GFR
Amon 1992 
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Notes • Abstract only• 4 excluded: transplantation, dialysis, compliance, non-response due to infection• Adverse effects equal across groups• Funding source: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement - says study is "prospective ran-
domized multi-centre study"
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding and lack of blinding could influence management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcomes of interest are laboratory based and unlikely to be affected by
knowledge of allocation
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Per-protocol analysis was used, 18% of the children randomised to either
treatment were excluded from analysis
Selective reporting (re-
porting bias)
High risk All pre-specified outcomes reported; however no full-text publication by De-
cember 2016
Other bias Unclear risk Insufficient information to permit judgement
Amon 1992  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Duration of follow-up: 32 weeks (8 weeks correction phase, 24 weeks maintenance phase)
Participants • Countries: Belgium, Netherlands• Setting: multicentre• Progressive kidney failure; SCr 375 to 1034 µmol/L; anaemic (Hb 5.3 to 10.2 g/dL and HCT 0.16 to 0.30
L/L)• Number: treatment group 1 (8); treatment group 2 (8); treatment group 3 (8)• Mean age (range): 23 to 68 years• Sex (M/F): 11/13• Exclusion criteria: other attributable causes for anaemia; acute illness in last 7 days; blood transfu-
sions within last 30 days
Interventions Correction phase
• Treatment group 1* Epoetin alpha IVI: 50 U/kg 3 times/week for 8 weeks
Frenken 1989 
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• Treatment group 2* Epoetin alpha IVI: 100 U/kg 3 times/week for 8 weeks• Treatment group 3* Epoetin alpha IVI: 150 U/kg 3 times/week for 8 weeks
Maintenance phase (at end of 8 weeks; non-randomised)
• Epoetin alfa IVI once/week commencing at 3 times the dose given during correction phase
Co-interventions
• Oral iron supplementation: up to 200 mg elemental iron/d• Folic acid: 2 weeks prior to inclusion and duration of study
Outcomes • Final Hb• Adverse events: hypertension, mortality
Notes • Two patients withdrawn at week 21 and 28; ESKD developed and dialysis therapy was started• One patient received a kidney transplant at week 30• One patient died during the maintenance phase and was excluded from further evaluation• Funding source: medication provided by Ortho Pharmaceutical Corporation (Raritan, New Jersey,
USA) and Cilag B.V. (Herentals, Belgium)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Insufficient information to permit judgement
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Lack of blinding could influence patient management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Primary outcome was laboratory based and unlikely to be influenced by lack
of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient information to permit judgement
Selective reporting (re-
porting bias)
Low risk All pre-specified outcomes reported
Other bias Low risk Medication provided by Ortho Pharmaceutical Corporation (Raritan, New Jer-
sey, USA) and Cilag B.V. (Herentals, Belgium)
Frenken 1989  (Continued)
 
 
Methods • Study design: parallel RCT, randomised 2:1• Study duration: August 2005 to May 2007
Gertz 2012 
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• Duration of follow-up: 30 days post study
Participants • Countries: Bosnia, Bulgaria, Croatia, Hungary, Israel, Poland, Romania, Russia, Serbia, Turkey• Setting: 47 centres• ≥ 18 years with CKD stage III or worse not on dialysis receiving maintenance treatment with epoetin
beta for ≥ 3 months and Hb ≥ 9.5 < 12.0 g/dL and no evidence of iron deficiency within the last 4 weeks• Number: treatment group 1 (193); treatment group 2 (95)• Mean age ± SD (years): treatment group 1 (34.1 ± 13.1); treatment group 2 (61.7 ± 15.7)• Sex (M/F): treatment group 1 (92/101); treatment group 2 (59/36)• Exclusion criteria: active bleeding; RBC transfusion within the last 3 months; female patients of child-
bearing potential; uncontrolled severe HTN; congestive heart failure (NYHA III or IV); severe metabolic
acidosis; current systemic infection or inflammatory disease; current malignant disease; resistance to
epoetin; known hypersensitivity to epoetin or excipients; known presence of antibodies to epoetin
Interventions Treatment group 1
• Epoetin theta (2000 and 4000 IU/0.5 mL): weekly dose of 38.1 ± 26.8 IU/kg for 24 weeks
Treatment group 2
• Epoetin beta (1000 or 4000 IU/0.3 mL): weekly dose of 37.7 ± 23.7 IU/Kg for 24 weeks• Dose adjusted to maintain Hb within a target interval defined as ± 1.0 g/dL of the baseline level and
≥ 9.5 to < 12.0 g/dL
Type of epoetin
• Epoetin beta: Recormin®• Epoetin theta: Eporatio®, Biopoin®
Co-interventions
• Iron administration
Outcomes • Change in Hb level from baseline to end of treatment, non-inferiority of epoetin theta to epoetin beta• Mean weekly dose of EPO• Percentage of subjects with dose changes• Percentage of Hb levels per subjects within target interval• Time course of Hb level• Percentage of subjects with Hb level within target interval at each week• Blood transfusions• Adverse effects/other safety variables• Tolerability• Immunogenicity
Notes • No anti-EPO antibodies detected• Funding source: "This clinical study and this article were sponsored by BioGeneriX AG, a member of
the Teva Group"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Central randomisation via an interactive voice response system
Allocation concealment
(selection bias)
Low risk "randomised to treatment by using central randomisation via IVRS"
Gertz 2012  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Similar syringes of intervention EPO
Administration of intervention medication by a person who was not part of the
study
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory-based outcome and unlikely to be influenced by blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 89% were included of those randomised were included in the ITT population
Selective reporting (re-
porting bias)
Low risk Studies pre-specified outcomes reported
Other bias High risk Study and paper writing assistance was sponsored by a Pharma
Gertz 2012  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Duration of follow-up: planned for 52 weeks
Participants • Country: Austria, Bulgaria, the Czech Republic, France, Germany, India, Poland, Romania, Russia and
Slovakia• Setting: 89 centres• ≥ 18 years; CKD stage III-V, Hb level ≥ 7.5 and < 11.0 g/dL on at least two visits during the screening
period; naïve to ESA treatment or with an ESA treatment-free period of ≥ 3 months before enrolment;
adequate iron status (serum ferritin ≥ 100 mg/L or transferrin saturation ≥ 20%)• Number: treatment group 1 (174); treatment group 2 (163)• Mean age, range (years): treatment group 1 (64.1, 19 to 88); treatment group 2 (64.9, 20 to 90)• Sex (M/F): treatment group 1 (77/97); treatment group 2 (65/98)• Exclusion criteria: chronic dialysis within the prior 6 months; non-renal anaemia; acute deterioration
of kidney function or blood transfusion during screening; suspicion of, or known, PRCA; any haema-
tological disorder; thrombocytopenia or leucopenia; evidence of uncontrolled diabetes, uncontrolled
hypertension, uncontrolled hyperparathyroidism or severe hepatic dysfunction; congestive heart fail-
ure and/or angina; myocardial infarction or stroke in the previous 6 months; acute or chronic infection;
previous gastrointestinal bleeding (within 6 months) or haemolysis; evidence of active malignancy
within the previous 5 years (except non-melanoma skin cancer); therapy with immunosuppressants
(other than corticosteroids for chronic disease) within 3 months of screening; or known allergy to test
products or hypersensitivity to mammalian-derived products.
Interventions Treatment group A
• HX575: 25 IU/kg 3 times/week or 75 IU/kg once/week SC
Treatment group B
• Epoetin alpha: 25 IU/kg 3 times/week or 75 IU/kg once/week
Both groups
• Dose adjusted after 5 weeks to maintain Hb levels between 10 to 12 g/dL
Outcomes • Safety and immunogenicity
Haag-Weber 2012 
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• Mean change in Hb from baseline to end of 13 weeks• Mean weekly EPO dose in week 11 to 13 weeks• Adverse effects
Notes • Change in Hb baseline to week 13: HX575 2.2 ± 0.9 g/dL; epoetin alpha 2.2 ± 1.0 g/dL• Study terminated due to 2 patients developing PRCA• Funding source: "This study was funded by Sandoz Biopharmaceuticals. Medical writing assistance in
the preparation of this paper was provided by Tony Reardon of Spirit Medical Communications and
funded by Sandoz Biopharmaceuticals"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk "block randomisation, stratified by center"
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Lack of blinding could influence patient management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory based outcome and unlikely to be influenced by blinding
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Analysis done per-protocol method.
Study terminated & data in uncertain number of subjects only available to 13
weeks
Selective reporting (re-
porting bias)
High risk Outcomes of interest for this review such as change in EPO dose, number
reaching target Hb were presented in ways that could not be used in a meta-
analysis
Other bias High risk Study and paper writing assistance was sponsored by a Pharma
Haag-Weber 2012  (Continued)
 
 
Methods • Study design: parallel, open-label RCT stratified by age and centre, 1:3• Study duration: not reported• Duration of follow-up: 24 weeks
Participants • Country: America, Argentina• Setting: multicentre• Children, 1 to 17 years with CKD and associated anaemia. IV or SC epoetin alfa or epoetin delta, with
Hb 10-13g/dL• Number: treatment group 1 (13); treatment group 2 (47)• Mean age (range): 11.8 years (1 to 17)• Sex (M/F): 38/22• Exclusion criteria: not reported
Knebel 2008 
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Interventions Treatment group 1
• Epoetin alpha: SC 24 to 190 IU/kg; IV 36 to 88 IU/kg
Treatment group 2
• Epoetin delta: SC 26 to 191 IU/kg; IV 54 to 769 IU/kg
Outcomes • Pharmacokinetic study
Notes • Funding source: analysis was funded by Shire Pharmaceuticals
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Phase III randomised, multi-centre study. appropriate 3:1 ratio to epoetin delta
or epoetin alfa
Allocation concealment
(selection bias)
Unclear risk No information provided other than that randomisation stratified by age and
centre
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Lack of blinding could influence patient management
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Primary outcome was laboratory based and unlikely to be influenced by lack
of blinding
Incomplete outcome data
(attrition bias) 
All outcomes
High risk No data on outcomes provided
Selective reporting (re-
porting bias)
High risk No data on outcomes provided
Other bias High risk Pharmaceutical study
Analysis funded by Shire Pharmaceuticals
Study terminated for commercial reasons
Knebel 2008  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Duration of follow-up: not reported
Participants • Country: Norway• Setting: paediatric centres• Children with CKD not on dialysis• Number: 29• Mean age (range): not reported• Sex (M/F): not reported
Kronborg 1994 
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• Exclusion criteria: not reported
Interventions • Treatment group 1• Epoetin beta (Recormon): 2 doses SC
Treatment group 2
• Epoetin alpha (Eprex): 2 doses SC
Control group
• Saline: frequency of injections not provided
Outcomes • Pain score through VAS and VDS
Notes • Abstract only available• Funding source not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk "Comparative double-blind randomised placebo controlled study" but unclear
how performed
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Said to double-blind but unclear how this was achieved
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Unclear who performed outcome assessment
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients received all injections and contributed to results
Selective reporting (re-
porting bias)
High risk Insufficient information to permit judgement (abstract only), however no full
text publication by December 2016
Other bias Unclear risk Insufficient information to permit judgement
Kronborg 1994  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: not reported• Duration of follow-up: 12 weeks
Participants • Country: Germany, France• Setting: multicentre• Adults with CKD & GFR < 45 mL/min not on dialysis with no prior use of ESA; Hb < 10.0 g/dL
Mignon 2000 
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• Number: treatment group 1 (23); treatment group 2 (15); treatment group 3 (13); treatment group 4
(14); control group (15)• Mean age ± SD (years): not reported• Sex (M/F): not reported• Exclusion criteria: not reported except dialysis patients excluded
Interventions Treatment group 1
• EPO delta (HMR4396) SC: 15 IU/kg twice weekly for 12 weeks
Treatment group 2
• EPO delta (HMR4396) SC: 50 IU/kg twice weekly for 12 weeks
Treatment group 3
• EPO delta (HMR4396) SC: 100 IU/kg twice weekly for 12 weeks
Treatment group 4
• EPO delta (HMR4396) SC: 200 IU/kg twice weekly for 12 weeks
Control group
• Epoetin alpha SC: 50 IU/kg twice weekly for 12 weeks
All groups
• Correction targets were HB > 11.5 g/dL for 2 weeks or single level of HB > 13.0 g/dL• When target achieved, dose titrated to maintain HB ≥ 10.5 g/dL
Outcomes • Total success: number with HB ≥ 11.5 g/dL for 2 consecutive weeks or > 13.0 g/dL on one visit and HB
maintained ≥ 11.5 g/dL for remainder of 12 weeks• Change in HB• Number with PRCA• Adverse effects
Notes • Data available only from three abstracts. EPO delta removed from sale by company for commercial
reasons and the studies were not completed
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk "12 week multi-centre, randomised, double blind parallel group study" but not
details provided
Allocation concealment
(selection bias)
Unclear risk No information provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Said to be double blind but no information provided
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Primary outcome was laboratory based and unlikely to be influenced by blind-
ing
Mignon 2000  (Continued)
Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
37
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No information provided. Abstracts only
Selective reporting (re-
porting bias)
High risk Abstracts only, no full text publication by December 2016
Other bias High risk Aventis Pharma/Shire PLC
Mignon 2000  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: August 2006 to February 2008• Duration of follow-up: 48 weeks (22 weeks initiation and maintenance phase; 22 weeks safety phase;
4 weeks post-treatment phase)
Participants • Country: USA• Setting: 77 centres• Adults with CKD stage 3 or 4 with: 1) no prior use of ESA & Hb < 10.5 g/dL; 2) no prior ESA & Hb < 11.0
g/dL with ≥ 1 g/dL Hb decrease in the past 12 months; or 3) no ESA within 2 months before screening
resulting in a ≥ 1 g/dL Hb decrease since stopping ESA therapy and Hb <11 g/dL• Number (analysed/randomised): treatment group 1 (104/121); treatment group 2 (94/124); treatment
group 3 (105/124)• Mean age ± SD (years): treatment group 1 (71.4 ± 12.88); treatment group 2 (68.8 ± 11.89); treatment
group 3 (69.0 ± 13.04)• Sex (M/F): treatment group 1 (45/76); treatment group 2 (45/79); treatment group 3 (39/85)• Exclusion criteria: Iron deficiency, with serum ferritin concentration < 50 ng/mL and transferrin satu-
ration < 20%; poorly controlled HTN; severe congestive heart failure or coronary artery disease; active
infection or inflammation that could affect the response to epoetin alfa therapy; uncontrolled or new
onset of seizures; deep venous thrombosis or pulmonary embolus within the prior 12 months; stroke,
transient ischaemic attack, acute coronary syndrome, or other arterial thrombosis within the prior 6
months; and requiring dialysis or anticipated to require dialysis during the study
Interventions Treatment group 1
• Epoetin alpha (Procrit®) SC: 50 IU/Kg 3 times/week. After 22 weeks the dose was adjusted to 10,000
IU weekly
Treatment group 2
• Epoetin alpha (Procrit®) SC: 10,000 IU weekly
Treatment group 3
• Epoetin alpha (Procrit®) SC: 20,000 IU every 2 weeks
Both groups
• Dose adjustment: epoetin withheld if Hb > 11.9 g/dL or if rise ≥ 1.5 g/dL in 2 weeks; 25% increase in
dose if Hb ≤ 10.5 g/dL & rise < 0.5 g/dL in the prior 2 weeks; 25% decrease in dose if Hb rise was ≥ 1.0
but < 1.5 g/dL in the prior 2 weeks
Outcomes • Change in Hb level from baseline to the average of Hb level over the last 8 weeks of the first 22 weeks
of treatment with EPO• Proportions of subjects with ≥1.0 g/dL increase in Hb level from baseline by week 9 of treatment with
EPO
Pergola 2009 
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Notes • Funding source: "This work was supported by Johnson & Johnson Pharmaceutical Research & Devel-
opment"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk "subjects ... were randomly assigned"
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label study
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory based outcome and unlikely to be influenced by blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients accounts for and modified ITT data used
Selective reporting (re-
porting bias)
Low risk Stated and important outcomes of interest were reported
Other bias High risk The study and its authorship were supported by pharmaceutical firm
Pergola 2009  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: June 2007 to March 2009• Duration of follow-up: 40 weeks (36 weeks treatment, 4 weeks post-treatment phase)
Participants • Country: USA• Setting: 53 centres• Adults with CKD stage 3 or 4 with Hb between 10.0 and 11.0 g/dL while on stable once weekly dose
of EPO• Number (analysed/randomised): treatment group 1 (107/108); treatment group 2 (106/107); treat-
ment group 3 (215/215)• Mean age ± SD (years): treatment group 1 (70.4 ± 13.04); treatment group 2 (71.7 ± 10.68); treatment
group 3 (71.1 ± 12.48)• Sex (M/F): treatment group 1 (40/67); treatment group 2 (34/72); treatment group 3 (89/126)• Exclusion criteria: iron deficiency; poorly controlled hypertension; severe congestive heart failure or
coronary artery disease; deep venous thrombosis or pulmonary embolus within the prior 12 months;
stroke, transient ischaemic attack, acute coronary syndrome, or other arterial thrombosis within the
prior 6 months; and dialysis or anticipated to require dialysis during the study
Interventions Treatment group 1
• Epoetin alpha (Procrit®) SC: pre-randomisation dose
Pergola 2010 
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Treatment group 2
• Epoetin alpha (Procrit®) SC: twice the pre-randomisation dose to a maximum of 20,000 IU
Treatment group 3
• Epoetin alpha (Procrit®) SC: 4 times the pre-randomisation dose to a maximum of 40,000 IU
Both groups
• Dose was adjusted to reach the target Hb range of 11.0 to 11.9 g/dL
Co-interventions
• Oral iron supplements or parenteral iron
Outcomes • Group 2 and 3 treatments with epoetin were non inferior to group 1, mean change in Hb level from
baseline to the average of the Hb over the last 12 weeks of treatment• Proportions of weeks in which each subjects maintain Hb between 11.0 and 11.9 g/dL• Safety parameters related to Hb-related endpoints and clinical safety parameters
Notes • Funding source: "This work was supported by Johnson & Johnson Pharmaceutical Research & Devel-
opment LLC"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Said that "subjects ... were randomly assigned"
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label study
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory-based outcome and unlikely to be influenced by blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All patients accounts for and modified ITT data used
Selective reporting (re-
porting bias)
Low risk Pre-specified outcomes mentioned
Other bias High risk The study and its authorship were supported by pharmaceutical firm
Pergola 2010  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: June 2002 to September 2003• Duration of follow-up: 16 weeks
PROMPT Study 2005 
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Participants • Country: USA• Setting: 91 centres• Adults with CKD; stable Hb ≥ 11 g/dL and receiving epoetin alfa• Number (analysed/randomised): treatment group 1 (108/130); treatment group 2 (114/131); treat-
ment group 3 (114/132); treatment group 4 (104/126)• Mean age ± SD (years): treatment group 1 (69.5 ± 11.4); treatment group 2 (66.7 ± 14.1); treatment
group 3 (69.7 ± 14.6); treatment group 4 (68.8 ± 12.4)• Sex (M/F): treatment group 1 (67/63); treatment group 2 (68/63); treatment group 3 (62/70); treatment
group 4 (67/59)• Exclusion criteria: uncontrolled HTN; known hypersensitivity to mammalian cell derived products or
human albumin; receiving dialysis or scheduled to receive dialysis during the course of the study; iron
deficiency despite intravenous iron therapy during the past six months; current diagnosis of anaemia
due to B12 or folate deficiencies, haemolysis, or gastrointestinal bleeding; severe congestive heart
failure (NYHA Class IV); and pregnancy, lactation or failure to use adequate contraception
Interventions Treatment group 1
• Epoetin alpha (Procrit®) SC: 10,000 IU once weekly
Treatment group 2
• Epoetin alpha (Procrit®) SC: 20,000 IU every 2 weeks
Treatment group 3
• Epoetin alpha (Procrit®) SC 30,000 IU every 3 weeks
Treatment group 4
• Epoetin alpha (Procrit®) SC: 40,000 IU every 4 weeks
All groups
• Dose reduction permitted only when Hb rose to > 13.0 g/dL or a rise of > 1.3 g/dL was attained in any
2-week period
Outcomes • Mean final Hb• Mean final score for each Quality of Life score• Change in Hb level over time• Hb maintenance ≥ 11.0 g/dL• Treatment failure• GFR change over time
Notes • Funding source: "This study was supported by a research grant from Ortho Biotech Clinical Affairs, LLC.
Financial disclosure: R. Provenzano, MD, FACP, has a consulting agreement with Ortho Biotech Prod-
ucts, L.P., and is on the Speakers Bureau and Advisory Board. S. Bhaduri, MD, owns stock in Johnson
& Johnson and is an employee of Ortho Biotech Clinical Affairs, LLC. A.K. Singh, MD, receives research
support and is on the Speakers Bureau for Ortho Biotech Products, L.P."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random sequence
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
PROMPT Study 2005  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label study
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory-based outcome and unlikely to be influenced by blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 90% of the patients who received epoetin were included in efficacy analysis
Selective reporting (re-
porting bias)
Low risk Pre-specified outcomes mentioned
Other bias High risk The study and its authorship were supported by pharmaceutical firm
PROMPT Study 2005  (Continued)
 
 
Methods • Study design: cross-over RCT• Study duration: not reported• Duration of follow-up: 12 weeks (4 weeks first phase, 4-week wash-out; 4 weeks second phase)
Participants • Country: Japan• Setting: Single centre• Adults with anaemia of pre-dialysis CKD, who had diabetes mellitus and were malnourished. not re-
ported whether patients had received EPO before• Number: 5• Mean age ± SD: 69.4 ± 9.04 years• sex (M/F): 3/2• Exclusion criteria: not reported
Interventions Treatment group 1
• Epoetin beta continuous SC infusion: 6000 IU/week at 36 IU/h for 4 weeks
Treatment group 2
• Epoetin beta single weekly SC dose: 6000 IU/week or 4 weeks
Cross-over study with 4-week washout period
Outcomes • Change in Hb• Change in reticulocyte count
Notes • Cross-over study and results not provided separately for first part of study• Funding source: "This work was supported in part by grants from the Ministry of Education and Cul-
ture, Japan, the Ministry of Health and Welfare, Japan, and the Foundation of Renal Disorders"
Risk of bias
Bias Authors' judgement Support for judgement
Sohmiya 1998 
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Random sequence genera-
tion (selection bias)
Unclear risk "The cross-over comparative study of two protocols was randomly performed
for each patient with wash out period of 4 weeks"
Allocation concealment
(selection bias)
Unclear risk Unclear. No information provided
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk No blinding performed
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk End points were laboratory-based
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Data reported on all patients for each treatment
Selective reporting (re-
porting bias)
High risk No report of adverse effects
Data not provided in format that allowed results to be included in meta-analy-
ses
Other bias Low risk Grants from Japanese Government and research organisations
Sohmiya 1998  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: September 2005 to October 2006• Duration of follow-up: 16 weeks
Participants • Country: USA• Setting: 37 centres• Adults with anaemia of CKD, absence of iron deficiency and negative urine pregnancy test within 7
days of study• Number (analysed/randomised): treatment group 1 (39/39); treatment group 2 (76/77); treatment
group 3 (72/73); treatment group 4 (72/73)• Mean age ± SD (years): treatment group 1 (65.2 ± 11.1); treatment group 2 (67.8 ± 13.6); treatment
group 3 (67.8 ± 14.4); treatment group 4 (66.9 ± 13.6)• Sex (M/F): treatment group 1 (14/25); treatment group 2 (33/43); treatment group 3 (32/40); treatment
group 4 (28/44)• Exclusion criteria: EPO in the prior 8 weeks; iron overload; breastfeeding mothers; poorly controlled
HTN, serum albumin < 2.6 g/dL; history of cardiovascular disease or thrombovascular events; new-
onset seizures within 3 months of study entry or uncontrolled seizures
Interventions Treatment group 1
• Epoetin alpha (Procrit®) SC: 10,000 IU weekly
Treatment group 2
• Epoetin alpha (Procrit®) SC: 20,000 IU every 2 weeks
Treatment group 3
Spinowitz 2008 
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• Epoetin alpha (Procrit®) SC: 20,000 IU every 4 weeks
Treatment group 4
• Epoetin alpha (Procrit®) SC: 20,000 IU every 4 weeks
All groups
• Dose adjustment permitted after 4 weeks if Hb fell outside of 11 to 12 g/dL range or rate of rise of Hb
fell outside the rate of rise of 0.5 to 1.0 g/dL in any 2 weeks
Co-interventions
• Oral elemental iron 200mg/d; parenteral iron at discretion of the site investigator
Outcomes • Change of Hb from baseline to end of study• Hb increase of > 1.0 g/dL from baseline• Time to Hb response• Proportion with Hb > 11.0 g/dL and an increase of ≥ 1.0 g/dL from baseline• Change in Hb over time• Proportion who received packed red cell transfusion• Number of units of packed red cells received• Weekly EPO dose
Notes • Funding source: Supported by Ortho Biotech Clinical Affairs, LLC
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation schedule
Allocation concealment
(selection bias)
Low risk Centrally generated using an interactive voice response system
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label study
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Laboratory-based outcome and unlikely to be influenced by blinding
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk The primary end points were presented for over 98% of the study population
using modified ITT analysis
Selective reporting (re-
porting bias)
Low risk Pre-specified outcomes mentioned
Other bias High risk The study and its authorship were supported by a pharmaceutical firm
Spinowitz 2008  (Continued)
BUN - blood urea nitrogen; CKD - chronic kidney disease; EPO - erythropoietin; ESA - erythropoiesis-stimulating agent/s; GFR - glomerular
filtration rate; Hb - haemoglobin; HCT - haematocrit; HTN - hypertension; ITT - intention-to-treat; IV - intravenous; IVI - IV infusion: M/
F - male/female; PRCA - pure red cell aplasia; RBC - red blood cell/s; RCT - randomised controlled trial; SC - subcutaneous; SCr - serum
creatinine; SD - standard deviation; VAS - visual analogue scale; VDS - verbal descriptive scale
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Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Brown 1988 Ineligible intervention; compares ESA with placebo
Clyne 1992 Ineligible intervention; compares ESA with no treatment
Duliege 2005 Phase 2 study of synthetic non-epoetin agent
Furukawa 1992 Pharmacokinetic study
Li 2004 Ineligible intervention; compares Bushen Jianpi Recipe + ESA with ESA
Meloni 2003 Ineligible intervention; compares short-acting ESA with no ESA
NCT00240734 Ineligible intervention; compares short-acting ESA with placebo
Study terminated because of slow enrolment and no results posted
NCT00492427 Ineligible intervention; compares long acting ESA with short-acting ESA
NCT00563355 Ineligible intervention; compares short-acting ESA with no treatment
Patel 2012 Ineligible intervention; compares extended duration of short-acting ESA with standard care for in-
stitution
Schwartz 1989 Ineligible intervention; compares short-acting ESA with placebo
Shaheen 1983 Ineligible intervention; compares short-acting ESA with no treatment
Singh 1999 Ineligible intervention; compares short-acting ESA with no treatment
Teehan 1990 Ineligible intervention; compares short-acting ESA with placebo
Teplan 1995 Ineligible intervention; compares short-acting ESA to no treatment
Yamazaki 1993 Unclear whether this study is randomised
Zheng 1992 Unclear whether this study is randomised
ESA - erythropoiesis-stimulating agent/s
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods • Open-label RCT
Participants Inclusion criteria
• Adults ≥ 18 years with or without dialysis treatment• Stable IV or SC maintenance therapy with an EU-approved ESA treatment or ESA naïve• Adequate iron substitution
Exclusion criteria
NCT01576341 
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• History of PRCA)or anti-EPO antibodies• Contraindications for ESA therapy• Serum albumin < 3.0 g/dL• Immunocompromised patients (immunosuppressive treatment, chemotherapy)• Hepatitis C infection on an active treatment or hepatitis B or human immunodeficiency virus (HIV)
infection• SLE• Symptomatic congestive heart failure, Unstable angina pectoris, or myocardial infarction within
6 months• History of malignancy of any organ system within the last 5 years• History of use of any non-EU approved ESA
Interventions • Drug: HX575 epoetin alfa (Sandoz) Eligible patients are scheduled to receive HX575 (INN: Epoetin
alfa) as a solution for injection in order to achieve or maintain the correction of renal anaemia.
Other name: Binocrit®, Epoetin alfa HEXAL®, Novicrit®, Abseamed®
Outcomes • Incidence of antibody formation against epoetin• Hb levels over time and change from baseline• Weekly epoetin dosage (IU and IU/kg) over time and change from baseline• Incidence and severity of AE, and of drug related AE
Notes • Study completed; last updated 11 November 2015
NCT01576341  (Continued)
 
 
Methods • Double-blind RCT
Participants Inclusion criteria:
• Patients with ESKD (stage CKD 5d), receiving stable SC maintenance therapy with Epogen® or Pr-
ocrit® at least once per week• Mean Hb level between 9.0 to 11.5 g/dL during the screening period• Adequate iron substitution
Exclusion criteria:
• Contraindications for ESA therapy• History of PRCA, or anti-EPO antibodies• Known HIV or Hepatitis B infection• Hepatitis C infection on an active treatment• Symptomatic congestive heart failure (New York Heart Association [NYHA] class III and IV)• Unstable angina pectoris, or cardiac infarction during the last 6 months prior to randomization• Percutaneous coronary intervention, or coronary artery bypass grafting during the last 6 months
prior to randomisation• History of malignancy of any organ system• SLE• Immunocompromised patients
Interventions • Drug: HX575 epoetin alfa Solution for subcutaneous injection. The drug is administered subcuta-
neously at least once per week over 52 weeks. The dose will be individually titrated to maintain
Hb levels between 10 to 11 g/dL. Other Names: Binocrit® (Europe) Epoetin alfa HEXAL® (Europe)
Novicrit® (Europe) Abseamed® (Europe).• Comparator: epoetin alfa
NCT01693029 
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Outcomes • Mean absolute change in Hb levels between the screening/baseline period (week -4 to day 1) and
the evaluation period (week 21 to week 28)• Change from baseline in Hb levels over time• Change from baseline in the weekly epoetin dosage (International Unit [IU] and IU/kg) over time• Incidence and severity of adverse events, and of drug related adverse events• Incidence of antibody formation against Epoetin
Notes • Study completed; last updated 1 June 2016
NCT01693029  (Continued)
AE - adverse events; CKD - chronic kidney disease; EPO - erythropoietin; ESA - erythropoiesis-stimulating agent/s; ESKD - end-stage kidney
disease; Hb - haemoglobin; HIV - human immunodeficiency virus; IV - intravenous; PRCA - pure red cell aplasia; RCT - randomised controlled
trial; SC - subcutaneous; SLE - Systemic lupus erythematous
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Epoetin alpha every 2 weeks versus weekly
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Change in haemoglobin level 4 785 Mean Difference (IV, Random,
95% CI)
-0.20 [-0.33, -0.07]
2 Number reaching target haemoglobin 4 798 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.93, 0.99]
3 Number of deaths 4 838 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.38, 2.07]
4 Adverse events 4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 RBC transfusions 3 580 Risk Ratio (M-H, Random, 95% CI) 1.56 [0.71, 3.45]
4.2 Hypertension 4 838 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.55, 1.32]
4.3 Thrombovascular events 4 838 Risk Ratio (M-H, Random, 95% CI) 1.41 [0.67, 3.00]
4.4 Adverse events leading to discontinu-
ation of therapy
1 258 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.20, 4.79]
 
 
Analysis 1.1.   Comparison 1 Epoetin alpha every 2 weeks versus weekly, Outcome 1 Change in haemoglobin level.
Study or subgroup Every two weeks Weekly Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Spinowitz 2008 66 11.4 (0.9) 36 11.5 (0.9) 11.87% -0.13[-0.5,0.24]
PROMPT Study 2005 114 11.9 (1.1) 108 12.2 (1.1) 20.33% -0.3[-0.58,-0.02]
Pergola 2009 124 1.3 (0.9) 124 1.6 (1) 28.5% -0.32[-0.56,-0.08]
Pergola 2010 106 -0.1 (0.8) 107 -0 (0.7) 39.3% -0.08[-0.28,0.12]
   
Total *** 410   375   100% -0.2[-0.33,-0.07]
Favours weekly 10.5-1 -0.5 0 Favours every two weeks
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Study or subgroup Every two weeks Weekly Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Tau2=0; Chi2=2.98, df=3(P=0.39); I2=0%  
Test for overall effect: Z=3.09(P=0)  
Favours weekly 10.5-1 -0.5 0 Favours every two weeks
 
 
Analysis 1.2.   Comparison 1 Epoetin alpha every 2 weeks versus
weekly, Outcome 2 Number reaching target haemoglobin.
Study or subgroup Two week-
ly EPO
Weekly EPO Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Spinowitz 2008 67/76 36/39 6.26% 0.96[0.84,1.08]
PROMPT Study 2005 102/114 101/108 14.61% 0.96[0.88,1.04]
Pergola 2009 115/124 119/124 25.2% 0.97[0.91,1.03]
Pergola 2010 102/106 107/107 53.93% 0.96[0.92,1]
   
Total (95% CI) 420 378 100% 0.96[0.93,0.99]
Total events: 386 (Two weekly EPO), 363 (Weekly EPO)  
Heterogeneity: Tau2=0; Chi2=0.06, df=3(P=1); I2=0%  
Test for overall effect: Z=2.47(P=0.01)  
Favours weekly 1 Favours two weekly
 
 
Analysis 1.3.   Comparison 1 Epoetin alpha every 2 weeks versus weekly, Outcome 3 Number of deaths.
Study or subgroup Every 2 weeks Weekly Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Spinowitz 2008 2/76 0/39 7.89% 2.6[0.13,52.81]
PROMPT Study 2005 2/130 1/128 12.56% 1.97[0.18,21.45]
Pergola 2010 3/107 4/108 33.01% 0.76[0.17,3.3]
Pergola 2009 4/125 6/125 46.53% 0.67[0.19,2.31]
   
Total (95% CI) 438 400 100% 0.89[0.38,2.07]
Total events: 11 (Every 2 weeks), 11 (Weekly)  
Heterogeneity: Tau2=0; Chi2=1.17, df=3(P=0.76); I2=0%  
Test for overall effect: Z=0.28(P=0.78)  
Favours every 2 weeks 5000.002 100.1 1 Favours weekly
 
 
Analysis 1.4.   Comparison 1 Epoetin alpha every 2 weeks versus weekly, Outcome 4 Adverse events.
Study or subgroup Every 2 weeks Every week Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.4.1 RBC transfusions  
Spinowitz 2008 1/76 0/39 6.21% 1.56[0.06,37.39]
Pergola 2010 6/107 4/108 40.99% 1.51[0.44,5.21]
Pergola 2009 8/125 5/125 52.8% 1.6[0.54,4.76]
Favours every 2 weeks 5000.002 100.1 1 Favours every week
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Study or subgroup Every 2 weeks Every week Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 308 272 100% 1.56[0.71,3.45]
Total events: 15 (Every 2 weeks), 9 (Every week)  
Heterogeneity: Tau2=0; Chi2=0, df=2(P=1); I2=0%  
Test for overall effect: Z=1.1(P=0.27)  
   
1.4.2 Hypertension  
Spinowitz 2008 0/76 0/39   Not estimable
PROMPT Study 2005 8/130 9/128 22.24% 0.88[0.35,2.2]
Pergola 2010 14/107 13/108 37.82% 1.09[0.54,2.2]
Pergola 2009 12/125 18/125 39.93% 0.67[0.34,1.33]
Subtotal (95% CI) 438 400 100% 0.85[0.55,1.32]
Total events: 34 (Every 2 weeks), 40 (Every week)  
Heterogeneity: Tau2=0; Chi2=0.95, df=2(P=0.62); I2=0%  
Test for overall effect: Z=0.72(P=0.47)  
   
1.4.3 Thrombovascular events  
Spinowitz 2008 0/76 1/39 5.61% 0.17[0.01,4.15]
PROMPT Study 2005 3/130 2/128 18.03% 1.48[0.25,8.69]
Pergola 2010 5/107 3/108 28.65% 1.68[0.41,6.86]
Pergola 2009 8/125 5/125 47.72% 1.6[0.54,4.76]
Subtotal (95% CI) 438 400 100% 1.41[0.67,3]
Total events: 16 (Every 2 weeks), 11 (Every week)  
Heterogeneity: Tau2=0; Chi2=1.8, df=3(P=0.62); I2=0%  
Test for overall effect: Z=0.9(P=0.37)  
   
1.4.4 Adverse events leading to discontinuation of therapy  
PROMPT Study 2005 3/130 3/128 100% 0.98[0.2,4.79]
Subtotal (95% CI) 130 128 100% 0.98[0.2,4.79]
Total events: 3 (Every 2 weeks), 3 (Every week)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.02(P=0.98)  
Test for subgroup differences: Chi2=2.46, df=1 (P=0.48), I2=0%  
Favours every 2 weeks 5000.002 100.1 1 Favours every week
 
 
Comparison 2.   Epoetin alpha every 4 weeks versus every 2 weeks
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Change in haemoglobin level 3 671 Mean Difference (IV, Random, 95%
CI)
-0.16 [-0.43, 0.10]
2 Number reaching target haemoglo-
bin
3 687 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.84, 1.07]
3 Number of deaths 3 724 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.33, 2.75]
4 Adverse events 3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 RBC transfusions 2 470 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.53, 2.98]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4.2 Hypertension 3 724 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.62, 1.69]
4.3 Arteriovenous complications 3 724 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.39, 2.68]
 
 
Analysis 2.1.   Comparison 2 Epoetin alpha every 4 weeks
versus every 2 weeks, Outcome 1 Change in haemoglobin level.
Study or subgroup Every 4 weeks Every 2 weeks Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
PROMPT Study 2005 104 11.4 (1.5) 114 11.9 (1.1) 27.07% -0.5[-0.86,-0.14]
Spinowitz 2008 65 11.4 (1) 66 11.4 (0.9) 29.98% 0.04[-0.28,0.36]
Pergola 2010 215 -0.2 (0.7) 107 -0.1 (0.8) 42.95% -0.09[-0.27,0.09]
   
Total *** 384   287   100% -0.16[-0.43,0.1]
Heterogeneity: Tau2=0.03; Chi2=5.43, df=2(P=0.07); I2=63.19%  
Test for overall effect: Z=1.2(P=0.23)  
Favours every 2 weeks 10.5-1 -0.5 0 Favours every 4 weeks
 
 
Analysis 2.2.   Comparison 2 Epoetin alpha every 4 weeks versus
every 2 weeks, Outcome 2 Number reaching target haemoglobin.
Study or subgroup Every 4 weeks Every 2 weeks Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
PROMPT Study 2005 79/104 102/114 29.68% 0.85[0.75,0.96]
Spinowitz 2008 62/72 67/76 29.83% 0.98[0.86,1.11]
Pergola 2010 208/215 102/106 40.48% 1.01[0.96,1.05]
   
Total (95% CI) 391 296 100% 0.95[0.84,1.07]
Total events: 349 (Every 4 weeks), 271 (Every 2 weeks)  
Heterogeneity: Tau2=0.01; Chi2=9.72, df=2(P=0.01); I2=79.42%  
Test for overall effect: Z=0.85(P=0.4)  
Favours every 2 weeks 20.5 1.50.7 1 Favours every 4 weeks
 
 
Analysis 2.3.   Comparison 2 Epoetin alpha every 4 weeks versus every 2 weeks, Outcome 3 Number of deaths.
Study or subgroup Every 4 weeks Every 2 weeks Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Spinowitz 2008 0/72 2/76 12.33% 0.21[0.01,4.32]
PROMPT Study 2005 1/124 2/130 19.71% 0.52[0.05,5.71]
Pergola 2010 9/215 3/107 67.96% 1.49[0.41,5.4]
   
Total (95% CI) 411 313 100% 0.95[0.33,2.75]
Favours every 4 weeks 1000.01 100.1 1 Favours every 2 weeks
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Study or subgroup Every 4 weeks Every 2 weeks Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 10 (Every 4 weeks), 7 (Every 2 weeks)  
Heterogeneity: Tau2=0; Chi2=1.68, df=2(P=0.43); I2=0%  
Test for overall effect: Z=0.09(P=0.93)  
Favours every 4 weeks 1000.01 100.1 1 Favours every 2 weeks
 
 
Analysis 2.4.   Comparison 2 Epoetin alpha every 4 weeks versus every 2 weeks, Outcome 4 Adverse events.
Study or subgroup Every 4 weeks Every 2 weeks Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.4.1 RBC transfusions  
Spinowitz 2008 2/72 1/76 13.21% 2.11[0.2,22.78]
Pergola 2010 14/215 6/107 86.79% 1.16[0.46,2.94]
Subtotal (95% CI) 287 183 100% 1.26[0.53,2.98]
Total events: 16 (Every 4 weeks), 7 (Every 2 weeks)  
Heterogeneity: Tau2=0; Chi2=0.21, df=1(P=0.65); I2=0%  
Test for overall effect: Z=0.52(P=0.6)  
   
2.4.2 Hypertension  
Spinowitz 2008 1/72 0/76 2.47% 3.16[0.13,76.44]
PROMPT Study 2005 9/124 8/130 29.57% 1.18[0.47,2.96]
Pergola 2010 26/215 14/107 67.96% 0.92[0.5,1.7]
Subtotal (95% CI) 411 313 100% 1.02[0.62,1.69]
Total events: 36 (Every 4 weeks), 22 (Every 2 weeks)  
Heterogeneity: Tau2=0; Chi2=0.69, df=2(P=0.71); I2=0%  
Test for overall effect: Z=0.09(P=0.93)  
   
2.4.3 Arteriovenous complications  
Spinowitz 2008 3/72 0/76 10.38% 7.38[0.39,140.48]
PROMPT Study 2005 3/124 3/130 32.59% 1.05[0.22,5.1]
Pergola 2010 7/215 5/107 57.04% 0.7[0.23,2.14]
Subtotal (95% CI) 411 313 100% 1.02[0.39,2.68]
Total events: 13 (Every 4 weeks), 8 (Every 2 weeks)  
Heterogeneity: Tau2=0.1; Chi2=2.27, df=2(P=0.32); I2=11.81%  
Test for overall effect: Z=0.03(P=0.97)  
Test for subgroup differences: Chi2=0.17, df=1 (P=0.92), I2=0%  
Favours every 4 weeks 10000.001 100.1 1 Favours every 2 weeks
 
 
Comparison 3.   Epoetin alpha di:erent doses given three times weekly
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Final haemoglobin 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
1.1 100 U/kg versus 50 U/kg 1   Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1.2 150 U/kg versus 50 U/kg 1   Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
2 Mean arterial BP 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
2.1 100 IU/kg/wk versus 50 IU/kg/wk 1   Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
2.2 150 IU/kg/wk versus 50 IU/kg/wk 1   Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
3 Final creatinine levels 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
3.1 100 IU/kg/wk versus 50 IU/kg/wk 1   Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
3.2 150 IU/kg/wk versus 50 IU/kg/wk 1   Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
 
 
Analysis 3.1.   Comparison 3 Epoetin alpha di:erent doses given three times weekly, Outcome 1 Final haemoglobin.
Study or subgroup 100-150 U/kg/wk 50 U/kg/wk Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
3.1.1 100 U/kg versus 50 U/kg  
Frenken 1989 8 11.8 (1.7) 8 11.1 (1.3) 0.7[-0.78,2.18]
   
3.1.2 150 U/kg versus 50 U/kg  
Frenken 1989 8 12.1 (1.1) 8 11.1 (1.3) 1[-0.18,2.18]
Favours 50 U/kg 42-4 -2 0 Favours 100-150 U/kg
 
 
Analysis 3.2.   Comparison 3 Epoetin alpha di:erent doses given three times weekly, Outcome 2 Mean arterial BP.
Study or subgroup 100-150 U/kg/wk 50 U/kg/wk Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
3.2.1 100 IU/kg/wk versus 50 IU/kg/wk  
Frenken 1989 8 113 (9) 8 98 (9) 15[6.18,23.82]
   
3.2.2 150 IU/kg/wk versus 50 IU/kg/wk  
Frenken 1989 8 109 (24) 8 98 (9) 11[-6.76,28.76]
Favours 100-150 U/kg 5025-50 -25 0 Favours 50 U/kg
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Analysis 3.3.   Comparison 3 Epoetin alpha di:erent doses
given three times weekly, Outcome 3 Final creatinine levels.
Study or subgroup 100-150 IU/kg/wk 50 IU/kg/wk Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
3.3.1 100 IU/kg/wk versus 50 IU/kg/wk  
Frenken 1989 8 790 (244) 8 780 (350) 10[-285.65,305.65]
   
3.3.2 150 IU/kg/wk versus 50 IU/kg/wk  
Frenken 1989 8 696 (187) 8 780 (350) -84[-358.98,190.98]
Favours 100-150 IU/kg/wk 500250-500 -250 0 Favours 50 IU/kg/wk
 
 
Comparison 4.   Epoetin alpha di:erent doses given every four weeks
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Final haemoglobin 1   Mean Difference (IV, Random, 95%
CI)
Totals not selected
2 Number reaching target haemoglo-
bin
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Number of deaths 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Adverse events 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
4.1 Hypertension 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Thrombovascular events 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 RBC transfusions 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 4.1.   Comparison 4 Epoetin alpha di:erent doses given every four weeks, Outcome 1 Final haemoglobin.
Study or subgroup 40,000 IU every 4 weeks 20,000 IU every 4 weeks Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Spinowitz 2008 65 11.4 (1) 62 11.2 (1.1) 0.17[-0.19,0.53]
Favours 20,000 IU 10.5-1 -0.5 0 Favours 40,000 IU
 
 
Analysis 4.2.   Comparison 4 Epoetin alpha di:erent doses given
every four weeks, Outcome 2 Number reaching target haemoglobin.
Study or subgroup 40,000 IU every 4 weeks 20,000 IU every 4 weeks Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Spinowitz 2008 62/72 58/72 1.07[0.92,1.24]
Favours 40,000 IU 20.5 1.50.7 1 Favours 20,000 IU
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Analysis 4.3.   Comparison 4 Epoetin alpha di:erent doses given every four weeks, Outcome 3 Number of deaths.
Study or subgroup 40,000 IU every 4 weeks 20,000 IU every 4 weeks Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Spinowitz 2008 0/72 1/72 0.33[0.01,8.05]
Favours 20,000 IU 1000.01 100.1 1 Favours 40,000 IU
 
 
Analysis 4.4.   Comparison 4 Epoetin alpha di:erent doses given every four weeks, Outcome 4 Adverse events.
Study or subgroup 40,000 IU every 4 weeks 20,000 IU every 4 weeks Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
4.4.1 Hypertension  
Spinowitz 2008 1/72 0/72 3[0.12,72.44]
   
4.4.2 Thrombovascular events  
Spinowitz 2008 3/72 1/72 3[0.32,28.17]
   
4.4.3 RBC transfusions  
Spinowitz 2008 2/72 2/72 1[0.14,6.91]
Favours 40,000 IU 1000.01 100.1 1 Favours 20,000 IU
 
 
Comparison 5.   Epoetin alpha IV versus subcutaneous administration
Outcome or subgroup title No. of
studies
No. of par-
ticipants
Statistical method Effect size
1 Final haemoglobin 1   Mean Difference (IV, Random, 95% CI) Totals not selected
 
 
Analysis 5.1.   Comparison 5 Epoetin alpha IV versus subcutaneous administration, Outcome 1 Final haemoglobin.
Study or subgroup IV SC Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Aggarwal 2002 10 8.6 (1.1) 10 9.6 (1.3) -0.99[-2.08,0.1]
Favours SC 42-4 -2 0 Favours IV
 
 
Comparison 6.   Epoetin theta versus epoetin beta
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Final Hb 1   Mean Difference (IV, Random, 95% CI) Totals not selected
2 Mean weekly epoetin dose 1   Mean Difference (IV, Random, 95% CI) Totals not selected
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
3 Deaths 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Adverse events 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
4.1 Hypertension 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 RBC transfusions 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Discontinuation of therapy 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 6.1.   Comparison 6 Epoetin theta versus epoetin beta, Outcome 1 Final Hb.
Study or subgroup Epoetin theta Epoetin beta Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Gertz 2012 193 11 (1) 95 11 (0.9) -0.02[-0.25,0.21]
Favours EPO beta 0.50.25-0.5 -0.25 0 Favours EPO theta
 
 
Analysis 6.2.   Comparison 6 Epoetin theta versus epoetin beta, Outcome 2 Mean weekly epoetin dose.
Study or subgroup Epoetin theta Epoetin beta Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Gertz 2012 193 38.1 (26.8) 95 37.7 (23.7) 0.4[-5.68,6.48]
Favours epoetin theta 105-10 -5 0 Favours epoetin beta
 
 
Analysis 6.3.   Comparison 6 Epoetin theta versus epoetin beta, Outcome 3 Deaths.
Study or subgroup Epoetin theta Epoetin beta Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Gertz 2012 5/193 1/95 2.46[0.29,20.77]
Favours epoetin theta 500.02 100.1 1 Favours beta
 
 
Analysis 6.4.   Comparison 6 Epoetin theta versus epoetin beta, Outcome 4 Adverse events.
Study or subgroup Epoetin theta Epoetin beta Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
6.4.1 Hypertension  
Gertz 2012 5/193 7/95 0.35[0.11,1.08]
   
6.4.2 RBC transfusions  
Gertz 2012 1/193 0/95 1.48[0.06,36.1]
Favours epoetin theta 500.02 100.1 1 Favours epoetin beta
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Study or subgroup Epoetin theta Epoetin beta Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
   
6.4.3 Discontinuation of therapy  
Gertz 2012 18/193 5/95 1.77[0.68,4.63]
Favours epoetin theta 500.02 100.1 1 Favours epoetin beta
 
 
A P P E N D I C E S
Appendix 1. Electronic search strategies
 
Database Search terms
CENTRAL 1. MeSH descriptor: [Renal Insufficiency] this term only
2. MeSH descriptor: [Renal Insufficiency, Chronic] explode all trees
3. MeSH descriptor: [Kidney Diseases] this term only
4. "chronic kidney" or "chronic renal":ti,ab,kw (Word variations have been searched)
5. CKF or CKD or CRF or CRD:ti,ab,kw (Word variations have been searched)
6. pre-dialy* or predialy*:ti,ab,kw (Word variations have been searched)
7. MeSH descriptor: [Uremia] explode all trees
8. uremi* or uraemi*:ti,ab,kw (Word variations have been searched)
9. {or #1-#8}
10.MeSH descriptor: [Anemia] explode all trees
11.anemi* or anaemi*:ti,ab,kw (Word variations have been searched)
12.{or #10-#11}
13.MeSH descriptor: [Erythropoietin] this term only
14.erythropoietin:ti,ab,kw (Word variations have been searched)
15.epoetin:ti,ab,kw (Word variations have been searched)
16.rhuepo:ti,ab,kw (Word variations have been searched)
17.EPO:ti,ab,kw (Word variations have been searched)
18.{or #13-#17}
19.{and #9, #12, #18}
MEDLINE 1. Renal Insufficiency/
2. exp Renal Insufficiency, Chronic/
3. Kidney Diseases/
4. (chronic kidney or chronic renal).tw.
5. (CKF or CKD or CRF or CRD).tw.
6. (pre-dialy$ or predialy$).tw.
7. exp Uremia/
8. ur$emi$.tw.
9. or/1-8
10.exp Anemia/
11.(anemia or anaemia).tw.
12.or/10-11
13.Erythropoietin/
14.erythropoietin.tw.
15.EPO.tw.
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16.rHuepo.tw.
17.epoetin.tw.
18.or/13-17
19.and/9,12,18
EMBASE 1. Kidney Disease/
2. Chronic Kidney Disease/
3. Kidney Failure/
4. Chronic Kidney Failure/
5. Kidney dysfunction/
6. (chronic kidney or chronic renal).tw.
7. (CKF or CKD or CRF or CRD).tw.
8. (pre-dialy$ or predialy$).tw.
9. or/1-8
10.exp anemia/
11.(anemia or anaemia).tw.
12.or/10-11
13.exp recombinant erythropoietin/
14.erythropoietin.tw.
15.EPO.tw.
16.rHuepo.tw.
17.epoetin.tw.
18.or/13-17
19.and/9,12,18
  (Continued)
 
Appendix 2. Risk of bias assessment tool
 
Potential source of bias Assessment criteria
Low risk of bias: Random number table; computer random number generator; coin tossing; shuf-
fling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be equivalent to being random).
High risk of bias: Sequence generated by odd or even date of birth; date (or day) of admission; se-
quence generated by hospital or clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory test or a series of tests; by avail-
ability of the intervention.
Random sequence genera-
tion
Selection bias (biased alloca-
tion to interventions) due to
inadequate generation of a
randomised sequence
Unclear: Insufficient information about the sequence generation process to permit judgement.
Low risk of bias: Randomisation method described that would not allow investigator/participant to
know or influence intervention group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequential-
ly numbered drug containers of identical appearance; sequentially numbered, opaque, sealed en-
velopes).
Allocation concealment
Selection bias (biased alloca-
tion to interventions) due to
inadequate concealment of al-
locations prior to assignment
High risk of bias: Using an open random allocation schedule (e.g. a list of random numbers); as-
signment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or
non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record num-
ber; any other explicitly unconcealed procedure.
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Unclear: Randomisation stated but no information on method used is available.
Low risk of bias: No blinding or incomplete blinding, but the review authors judge that the outcome
is not likely to be influenced by lack of blinding; blinding of participants and key study personnel
ensured, and unlikely that the blinding could have been broken.
High risk of bias: No blinding or incomplete blinding, and the outcome is likely to be influenced by
lack of blinding; blinding of key study participants and personnel attempted, but likely that the
blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.
Blinding of participants and
personnel
Performance bias due to
knowledge of the allocated
interventions by participants
and personnel during the
study
Unclear: Insufficient information to permit judgement
Low risk of bias: No blinding of outcome assessment, but the review authors judge that the out-
come measurement is not likely to be influenced by lack of blinding; blinding of outcome assess-
ment ensured, and unlikely that the blinding could have been broken.
High risk of bias: No blinding of outcome assessment, and the outcome measurement is likely to be
influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could
have been broken, and the outcome measurement is likely to be influenced by lack of blinding.
Blinding of outcome assess-
ment
Detection bias due to knowl-
edge of the allocated interven-
tions by outcome assessors.
Unclear: Insufficient information to permit judgement
Low risk of bias: No missing outcome data; reasons for missing outcome data unlikely to be relat-
ed to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar reasons for missing data across
groups; for dichotomous outcome data, the proportion of missing outcomes compared with ob-
served event risk not enough to have a clinically relevant impact on the intervention effect esti-
mate; for continuous outcome data, plausible effect size (difference in means or standardized dif-
ference in means) among missing outcomes not enough to have a clinically relevant impact on ob-
served effect size; missing data have been imputed using appropriate methods.
High risk of bias: Reason for missing outcome data likely to be related to true outcome, with either
imbalance in numbers or reasons for missing data across intervention groups; for dichotomous
outcome data, the proportion of missing outcomes compared with observed event risk enough to
induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausi-
ble effect size (difference in means or standardized difference in means) among missing outcomes
enough to induce clinically relevant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that assigned at randomisation; potentially
inappropriate application of simple imputation.
Incomplete outcome data
Attrition bias due to amount,
nature or handling of incom-
plete outcome data.
Unclear: Insufficient information to permit judgement
Low risk of bias: The study protocol is available and all of the study’s pre-specified (primary and
secondary) outcomes that are of interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published reports include all expected out-
comes, including those that were pre-specified (convincing text of this nature may be uncommon).
High risk of bias: Not all of the study’s pre-specified primary outcomes have been reported; one or
more primary outcomes is reported using measurements, analysis methods or subsets of the data
(e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-
specified (unless clear justification for their reporting is provided, such as an unexpected adverse
effect); one or more outcomes of interest in the review are reported incompletely so that they can-
not be entered in a meta-analysis; the study report fails to include results for a key outcome that
would be expected to have been reported for such a study.
Selective reporting
Reporting bias due to selective
outcome reporting
Unclear: Insufficient information to permit judgement
Other bias Low risk of bias: The study appears to be free of other sources of bias.
  (Continued)
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High risk of bias: Had a potential source of bias related to the specific study design used; stopped
early due to some data-dependent process (including a formal-stopping rule); had extreme base-
line imbalance; has been claimed to have been fraudulent; had some other problem.
Bias due to problems not cov-
ered elsewhere in the table
Unclear: Insufficient information to assess whether an important risk of bias exists; insufficient ra-
tionale or evidence that an identified problem will introduce bias.
  (Continued)
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
Removal of the comparison of short-acting ESAs in evaluating the benefits and harms of diCerent Hb or HCT targets in CKD patients
receiving ESA treatment for anaemia as this is included in another systematic review (Strippoli 2006).
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Renal Dialysis;  Anemia  [blood]  [*drug therapy];  Epoetin Alfa  [*administration & dosage];  Erythropoietin  [*administration & dosage];
  Hematinics  [*administration & dosage];  Hemoglobin A;  Injections, Intravenous;  Randomized Controlled Trials as Topic;  Recombinant
Proteins  [administration & dosage];  Renal InsuCiciency, Chronic  [*blood]
MeSH check words
Adult; Child; Humans
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